<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="systematic-review" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Public Health</journal-id><journal-id journal-id-type="iso-abbrev">Front Public Health</journal-id><journal-id journal-id-type="pmc-domain-id">2277</journal-id><journal-id journal-id-type="pmc-domain">frontpubhealth</journal-id><journal-id journal-id-type="publisher-id">Front. Public Health</journal-id><journal-title-group><journal-title>Frontiers in Public Health</journal-title></journal-title-group><issn pub-type="epub">2296-2565</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9046659</article-id><article-id pub-id-type="pmcid-ver">PMC9046659.1</article-id><article-id pub-id-type="pmcaid">9046659</article-id><article-id pub-id-type="pmcaiid">9046659</article-id><article-id pub-id-type="pmid">35493393</article-id><article-id pub-id-type="doi">10.3389/fpubh.2022.829176</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Public Health</subject><subj-group><subject>Systematic Review</subject></subj-group></subj-group></article-categories><title-group><article-title>Safety, Immunogenicity, and Efficacy of COVID-19 Vaccines in Adolescents, Children, and Infants: A Systematic Review and Meta-Analysis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Du</surname><given-names initials="Y">Yuxuan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/1586054/overview"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chen</surname><given-names initials="L">Long</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Shi</surname><given-names initials="Y">Yuan</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="c001" ref-type="corresp">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="http://loop.frontiersin.org/people/734290/overview"/></contrib></contrib-group><aff id="aff1"><sup>1</sup><institution>Department of Neonatology, Children's Hospital of Chongqing Medical University</institution>, <addr-line>Chongqing</addr-line>, <country>China</country></aff><aff id="aff2"><sup>2</sup><institution>National Clinical Research Center for Child Health and Disorders</institution>, <addr-line>Chongqing</addr-line>, <country>China</country></aff><aff id="aff3"><sup>3</sup><institution>Ministry of Education Key Laboratory of Child Development and Disorders</institution>, <addr-line>Chongqing</addr-line>, <country>China</country></aff><aff id="aff4"><sup>4</sup><institution>China International Science and Technology Cooperation Base of Child Development and Critical Disorders</institution>, <addr-line>Chongqing</addr-line>, <country>China</country></aff><aff id="aff5"><sup>5</sup><institution>Chongqing Key Laboratory of Pediatrics</institution>, <addr-line>Chongqing</addr-line>, <country>China</country></aff><author-notes><fn fn-type="edited-by"><p>Edited by: Janja Marc, University of Ljubljana, Slovenia</p></fn><fn fn-type="edited-by"><p>Reviewed by: Dana Dolanov&#225;, Masaryk University, Czechia; Arcadio A. Cerda, University of Talca, Chile</p></fn><corresp id="c001">*Correspondence: Yuan Shi <email>shiyuan@hospital.cqmu.edu.cn</email></corresp><fn fn-type="other" id="fn001"><p>This article was submitted to Infectious Diseases &#8211; Surveillance, Prevention and Treatment, a section of the journal Frontiers in Public Health</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>4</month><year>2022</year></pub-date><pub-date pub-type="collection"><year>2022</year></pub-date><volume>10</volume><issue-id pub-id-type="pmc-issue-id">400439</issue-id><elocation-id>829176</elocation-id><history><date date-type="received"><day>05</day><month>12</month><year>2021</year></date><date date-type="accepted"><day>24</day><month>3</month><year>2022</year></date></history><pub-history><event event-type="pmc-release"><date><day>14</day><month>04</month><year>2022</year></date></event><event event-type="pmc-live"><date><day>29</day><month>04</month><year>2022</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2022-06-10 10:16:43.577"><day>10</day><month>06</month><year>2022</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2022 Du, Chen and Shi.</copyright-statement><copyright-year>2022</copyright-year><copyright-holder>Du, Chen and Shi</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fpubh-10-829176.pdf"/><abstract><sec><title>Background</title><p>As the epidemic progresses, universal vaccination against COVID-19 has been the trend, but there are still some doubts about the efficacy and safety of COVID-19 vaccines in adolescents, children, and even infants.</p></sec><sec><title>Purpose</title><p>To evaluate the safety, immunogenicity, and efficacy of COVID-19 vaccines in the population aged 0&#8211;17 years.</p></sec><sec><title>Method</title><p>A comprehensive search for relevant randomized controlled trials (RCTs) was conducted in PubMed, Embase, and the Cochrane Library from inception to November 9, 2021. All data were pooled by RevMan 5.3 statistical software, with risk ratio (RR) and its 95% confidence interval as the effect measure. This study protocol was registered on PROSPERO (CRD42021290205).</p></sec><sec><title>Results</title><p>There was a total of six randomized controlled trials included in this systematic review and meta-analysis, enrolling participants in the age range of 3&#8211;17 years, and containing three types of COVID-19 vaccines. Compared with mRNA vaccines and adenovirus vector vaccines, inactivated vaccines have a more satisfactory safety profile, both after initial (RR 1.40, 95% CI 1.04&#8211;1.90, <italic toggle="yes">P</italic> = 0.03) and booster (RR 1.84, 95% CI 1.20&#8211;2.81, <italic toggle="yes">P</italic> = 0.005) vaccination. The risk of adverse reactions was significantly increased after the first and second doses, but there was no significant difference between the first two doses (RR 1.00, 95%CI 0.99&#8211;1.02, <italic toggle="yes">P</italic> = 0.60). Nevertheless, the two-dose regimen is obviously superior to the single-dose schedule for immunogenicity and efficacy. After booster vaccination, both neutralizing antibodies (RR 144.80, 95%CI 44.97&#8211;466.24, <italic toggle="yes">P</italic> &lt; 0.00001) and RBD-binding antibodies (RR 101.50, 95%CI 6.44&#8211;1,600.76, <italic toggle="yes">P</italic> = 0.001) reach optimal levels, but the cellular immune response seemed not to be further enhanced. In addition, compared with younger children, older children and adolescents were at significantly increased risk of adverse reactions after vaccination, with either mRNA or inactivated vaccines, accompanied by a stronger immune response.</p></sec><sec><title>Conclusion</title><p>The available evidence suggests that the safety, immunogenicity and efficacy of COVID-19 vaccines are acceptable in people aged 3&#8211;17 years. However, there is an urgent need for additional multicenter, large-sample studies, especially in younger children under 3 years of age and even in infants, with long-term follow-up data.</p></sec><sec><title>Systematic Review Registration</title><p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021290205" ext-link-type="uri">https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021290205</ext-link>, identifier: CRD42021290205.</p></sec></abstract><kwd-group><kwd>COVID-19 vaccine</kwd><kwd>adolescents</kwd><kwd>child</kwd><kwd>infant</kwd><kwd>randomized controlled trial</kwd><kwd>meta-analysis</kwd></kwd-group><counts><fig-count count="3"/><table-count count="9"/><equation-count count="0"/><ref-count count="52"/><page-count count="15"/><word-count count="9441"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>It is the epidemic of coronavirus disease 2019 (COVID-19) that has placed a heavy burden on people worldwide, both physically and mentally (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). In order to control the epidemic, various types of COVID-19 vaccines have sprung up around the world, but the vast majority have only been approved for adults (<xref rid="B3" ref-type="bibr">3</xref>). However, with the prevalence of the Omicron variant, a highly divergent variant of syndrome coronavirus 2 (SARS-CoV-2), immune protection for adolescents, children and even infants seems to be imminent. Following the approval of CoronaVac for children aged 3&#8211;17 years, the BNT162b2-mRNA vaccine was urgently approved for children aged 5 years and older on November 2, 2021 (<xref rid="B4" ref-type="bibr">4</xref>). The sequential authorization of two different vaccines announces that the focus of vaccination is gradually shifting to younger children, as the fight against the epidemic progresses, which not only helps protect children's health and interrupt community epidemics but also promotes educational equity and economic recovery (<xref rid="B5" ref-type="bibr">5</xref>).</p><p>Compared with adults, teenagers and children infected with SARS-CoV-2 generally present with milder symptoms (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>). Therefore, the benefits of COVID-19 vaccines may not be as pronounced in this group as in adults (<xref rid="B8" ref-type="bibr">8</xref>). However, the possibility of critical illnesses, such as multisystemic inflammatory syndrome in children (MIS-C) (<xref rid="B9" ref-type="bibr">9</xref>), cannot be ruled out in this population, especially in those with underlying disease (<xref rid="B10" ref-type="bibr">10</xref>). Moreover, if left unchecked, this population has the potential to become a transit reservoir for SARS-CoV-2, leading to widespread community epidemics (<xref rid="B11" ref-type="bibr">11</xref>&#8211;<xref rid="B13" ref-type="bibr">13</xref>). Furthermore, vaccination helps promote regular back-to-school education (<xref rid="B14" ref-type="bibr">14</xref>), which not only prevents online instructions from becoming a barrier to education for poor students, but also removes the worry of working parents (<xref rid="B5" ref-type="bibr">5</xref>). In addition, maintaining good social activities also contributes to good psychological growth and sound character building in young children (<xref rid="B15" ref-type="bibr">15</xref>).</p><p>Advancing the childhood vaccination process should begin by eliminating parent's vaccination hesitancy. However, it is parental doubts about the safety, efficacy, and necessity of vaccinations that are holding back the process (<xref rid="B16" ref-type="bibr">16</xref>&#8211;<xref rid="B19" ref-type="bibr">19</xref>). After all, although a large number of vaccines have been shown to be safe and effective in adults, including the elderly (<xref rid="B20" ref-type="bibr">20</xref>&#8211;<xref rid="B27" ref-type="bibr">27</xref>), there is still a gap in research data for people under the age of 18. Considering the limited available clinical evidence and the urgency of advancing the vaccination process, we plan to conduct a meta-analysis based on existing randomized controlled trials (RCTs), to comprehensively evaluate the safety, immunogenicity, and efficacy of various COVID-19 vaccines in adolescents, children, and even infants.</p></sec><sec sec-type="methods" id="s2"><title>Methods</title><p>The systematic review and meta-analysis was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines (<xref rid="B28" ref-type="bibr">28</xref>), with a study protocol registered in the International Prospective Register of Systematic Evaluations database (CRD42021290205).</p><sec><title>Search Strategy</title><p>We conducted a comprehensive search in Pubmed, Embase, and Cochrane Library databases from inception to November 9, 2021, using &#8220;COVID-19 Vaccines,&#8221; &#8220;SARS-CoV-2,&#8221; &#8220;COVID-19,&#8221; &#8220;Adolescent,&#8221; &#8220;Child,&#8221; &#8220;Infant&#8221; and &#8220;Randomized controlled trial&#8221; as medical subject headings (MeSH) terms. The search details can be found in the <xref rid="SM1" ref-type="supplementary-material">Supplementary Material</xref>. The search in the clinical trials registers (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://clinicaltrials.gov/" ext-link-type="uri">Clinical Trials.gov</ext-link>, an ongoing NIH trial registry) was also performed to find potentially available studies. The electronic database search was additionally supplemented by a manual search of the reference lists of relevant systematic reviews and key articles.</p></sec><sec><title>Study Selection</title><p>Only randomized controlled trials were eligible, with no restrictions on language or publication status; cohort studies, case-control studies, single-arm studies, cross-sectional studies, case reports, reviews, comments, and letters were all excluded. These RCTs were conducted in healthy humans aged 0&#8211;17 years, with various types of COVID-19 vaccines as interventions, and placebo, adjuvant, or other vaccines as controls. The following statistical information should be provided as outcome indicators: (1) the incidence of adverse events after vaccination, including total adverse reactions, local adverse reactions, systemic adverse reactions, and any specific adverse reactions, (2) humoral immune responses, including the seroconversion after vaccination, (3) cellular immune responses, such as IFN-&#947; enzyme-linked immunospot, (4) incidence of confirmed COVID-19 post-vaccination. After removing duplicate records, two review authors (YD and LC) independently assessed the titles and abstracts of all records, and then conducted a full-text review with predetermined criteria. Disagreements were resolved by consulting a third author (YS).</p></sec><sec><title>Data Extraction</title><p>Specific bibliographic software EndNote X9 was used to manage the literature. Using a pre-developed data extraction form in Microsoft Excel, two authors independently extracted the following data: name of the first author, date of publication, study protocol, baseline characteristics of participants, sample size, intervention details, and outcome indicators. The seroconversion was defined as at least a fourfold increase in geometric mean titres (GMT) from baseline after vaccination. A secondary case definition of COVID-19 was also adopted, according to which patients were diagnosed with COVID-19 as long as they were positive for SARS-CoV-2 by RT-PCR and accompanied by one or more associated symptoms. In order to avoid missing data as much as possible, we carefully read the original text and supplementary materials of the included studies. If the original article grouped vaccinees according to age, dose of vaccination, etc., we would combine the data for each subgroup. If the original article did not provide the data in the form we expected, the required data would be calculated manually based on the information provided. When the required dichotomous variables were provided in the form of totals and percentages, we would obtain the available data by calculating the product. When the original text did not provide the information we needed, we attempted to obtain the corresponding information from the supplementary material. Considering the limited time, we did not contact the corresponding author to obtain the original data. In case of any disagreement, consensus would be reached through discussion or consultation with a third authors (YS).</p></sec><sec><title>Risk of Bias Assessment and Evidence Quality Assessment</title><p>To evaluate the methodological quality of the studies, two reviewer (YD and LC) independently assessed the risk of each study according to the Cochrane collaboration tool for assessing the risk of bias (Rob) (<xref rid="B29" ref-type="bibr">29</xref>). In order to appraise the quality and certainty of the evidence, these two authors (YD and LC) also assessed the reliability of the primary results by Gradepro 3.6 software, according to the Grades of Recommendation, Assessment, Development, and Evaluation (GRADE) standard. Any differences in the assessment process would be resolved by consulting the third reviewer (YS). Considering that the currently available literature may be limited, we would pool all studies regardless of quality.</p></sec><sec><title>Data Synthesis and Analysis</title><p>We used RevMan 5.3 statistical software to pool dichotomous outcomes, with the risk ratio (RR) and its 95% confidence interval (CI) as the effect measures. RR &gt; 1 implies a higher risk in the observation group, and <italic toggle="yes">P</italic> &lt; 0.05 indicates that this difference is statistically significant. The <italic toggle="yes">I</italic><sup>2</sup> statistic was used to estimate the level of heterogeneity, and significant heterogeneity was considered when the <italic toggle="yes">I</italic><sup>2</sup> value was &gt;50% (<xref rid="B30" ref-type="bibr">30</xref>). Following the recommendations of the Cochrane Handbook (<xref rid="B29" ref-type="bibr">29</xref>) and taking into account the different characteristics of the included studies (<xref rid="B31" ref-type="bibr">31</xref>), all data would be pooled by using random-effects models, regardless of the heterogeneity. However, if there were &lt;5 studies available, the random-effects model would no longer be applicable. In this case, the fixed-effects model would be chosen to pool the data. To trace the source of heterogeneity, we performed sensitivity analyses by excluding pooled studies one by one. Furthermore, subgroup analyses were conducted according to the number of vaccinations, type of vaccines, age of the recipients, and specific adverse reactions. When appropriate, direct comparisons were also conducted between prime and boost vaccinations, as well as among different ages. In addition, if ten or more RCT studies were eventually included, the funnel plot analysis of the primary outcome was planned to assess publication bias (<xref rid="B32" ref-type="bibr">32</xref>).</p></sec></sec><sec sec-type="results" id="s3"><title>Results</title><sec><title>Characteristics of the Included Studies</title><p>In this meta-analysis, a total of 1,166 citations were retrieved, and after removing duplicates, we screened 805 records based on title and abstract, of which 766 were determined to be irrelevan. The remaining 40 articles were evaluated in full text and 34 of them were excluded for various reasons. Finally, a total of 6 studies were included (<xref rid="B33" ref-type="bibr">33</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>), of which 1 trial was identified by manual search. No relevant trials providing available outcome indicators were found on ClinicalTrials.gov. The flow chart for identifying and selecting the studies was presented in <xref rid="F1" ref-type="fig">Figure 1</xref>. These six RCTs included three types of COVID-19 vaccines, with mRNA vaccines being the most studied (60%) (<xref rid="B33" ref-type="bibr">33</xref>&#8211;<xref rid="B35" ref-type="bibr">35</xref>), followed by inactivated vaccines (40%) (<xref rid="B35" ref-type="bibr">35</xref>, <xref rid="B36" ref-type="bibr">36</xref>) and adenoviral vector vaccines (20%) (<xref rid="B38" ref-type="bibr">38</xref>), all with saline or aluminum hydroxide adjuvants as controls. A total of 9,962 participants were enrolled, ranging in age from 3 to 17 years old. All participants received a two-dose injection, except for the vaccinees in one RCT (<xref rid="B37" ref-type="bibr">37</xref>), who received a three-dose regimen. In the two RCTs studying inactivated vaccines (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>), investigators grouped subjects according to age and the dose of vaccine administered. The characteristics of the included studies were summarized in <xref rid="T1" ref-type="table">Table 1</xref>. Overall, the risk of bias in these studies was low, with the main risk factors being incomplete outcome data and other biases, as shown in detail in <xref rid="F2" ref-type="fig">Figures 2</xref>, <xref rid="F3" ref-type="fig">3</xref>.</p><fig position="float" id="F1" orientation="portrait"><label>Figure 1</label><caption><p>Flow chart of study identification and selection.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpubh-10-829176-g0001.jpg"/></fig><table-wrap position="float" id="T1" orientation="portrait"><label>Table 1</label><caption><p>The characteristics of the included studies.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" align="left" rowspan="1" colspan="1">
<bold>References</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Clinical trials registration</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Phase</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Age range</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Type of vaccine</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Dose of administration</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Number of scheduled doses (time of inoculations)</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Control</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Number of observation group</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>Number of control group</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Ali et al. (<xref rid="B33" ref-type="bibr">33</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04649151">NCT04649151</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Phase 2/3</td><td valign="top" align="left" rowspan="1" colspan="1">12&#8211;17</td><td valign="top" align="left" rowspan="1" colspan="1">mRNA-1273 vaccine (mRNA vaccine)</td><td valign="top" align="left" rowspan="1" colspan="1">100 &#956;g/dose</td><td valign="top" align="left" rowspan="1" colspan="1">Prime and boost inoculation (0, 28 days)</td><td valign="top" align="left" rowspan="1" colspan="1">Saline</td><td valign="top" align="left" rowspan="1" colspan="1">2,486</td><td valign="top" align="left" rowspan="1" colspan="1">1,240</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Frenck et al. (<xref rid="B34" ref-type="bibr">34</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04368728">NCT04368728</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Phase 3</td><td valign="top" align="left" rowspan="1" colspan="1">12&#8211;15</td><td valign="top" align="left" rowspan="1" colspan="1">BNT162b2 Covid-19 Vaccine (mRNA vaccine)</td><td valign="top" align="left" rowspan="1" colspan="1">30 &#956;g/dose</td><td valign="top" align="left" rowspan="1" colspan="1">Prime and boost inoculation (0, 21 days)</td><td valign="top" align="left" rowspan="1" colspan="1">Saline</td><td valign="top" align="left" rowspan="1" colspan="1">1,131</td><td valign="top" align="left" rowspan="1" colspan="1">1,129</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Walter et al. (<xref rid="B35" ref-type="bibr">35</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04816643">NCT04816643</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Phase 2/3</td><td valign="top" align="left" rowspan="1" colspan="1">5&#8211;11</td><td valign="top" align="left" rowspan="1" colspan="1">BNT162b2 Covid-19 Vaccine (mRNA vaccine)</td><td valign="top" align="left" rowspan="1" colspan="1">10 &#956;g/dose</td><td valign="top" align="left" rowspan="1" colspan="1">Prime and boost inoculation (0, 21 days)</td><td valign="top" align="left" rowspan="1" colspan="1">Saline</td><td valign="top" align="left" rowspan="1" colspan="1">1,518</td><td valign="top" align="left" rowspan="1" colspan="1">750</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Han et al. (<xref rid="B36" ref-type="bibr">36</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04551547">NCT04551547</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Phase 1/2</td><td valign="top" align="left" rowspan="1" colspan="1">3&#8211;17 <bold>(</bold>3&#8211;5; 6&#8211;11; 12&#8211;17)</td><td valign="top" align="left" rowspan="1" colspan="1">CoronaVac (Inactivated vaccine)</td><td valign="top" align="left" rowspan="1" colspan="1">1.5 or 3 &#956;g/dose</td><td valign="top" align="left" rowspan="1" colspan="1">Prime and boost inoculation (0, 28 days)</td><td valign="top" align="left" rowspan="1" colspan="1">Alum</td><td valign="top" align="left" rowspan="1" colspan="1">436</td><td valign="top" align="left" rowspan="1" colspan="1">114</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Xia et al., (<xref rid="B37" ref-type="bibr">37</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1">ChiCTR2000032459</td><td valign="top" align="left" rowspan="1" colspan="1">Phase 1/2</td><td valign="top" align="left" rowspan="1" colspan="1">3&#8211;17 (3&#8211;5; 6&#8211;12; 13&#8211;17)</td><td valign="top" align="left" rowspan="1" colspan="1">BBIBP-COV (Inactivated vaccine)</td><td valign="top" align="left" rowspan="1" colspan="1">2 ug, 4 ug or 8 &#956;g/dose</td><td valign="top" align="left" rowspan="1" colspan="1">Three doses (0, 28, and 56 days)</td><td valign="top" align="left" rowspan="1" colspan="1">Saline and aluminum hydroxide adjuvant</td><td valign="top" align="left" rowspan="1" colspan="1">756</td><td valign="top" align="left" rowspan="1" colspan="1">252</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Zhu et al. (<xref rid="B38" ref-type="bibr">38</xref>)</td><td valign="top" align="left" rowspan="1" colspan="1"><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04566770">NCT04566770</ext-link></td><td valign="top" align="left" rowspan="1" colspan="1">Phase 2</td><td valign="top" align="left" rowspan="1" colspan="1">6&#8211;17</td><td valign="top" align="left" rowspan="1" colspan="1">Ad5-vectored COVID-19 vaccine (Adenovirus vaccine)</td><td valign="top" align="left" rowspan="1" colspan="1">0.3 ml/dose</td><td valign="top" align="left" rowspan="1" colspan="1">Prime and boost inoculation (0, 56 days)</td><td valign="top" align="left" rowspan="1" colspan="1">Placebo containing the same excipients as the vaccine, without viral particles</td><td valign="top" align="left" rowspan="1" colspan="1">100</td><td valign="top" align="left" rowspan="1" colspan="1">50</td></tr></tbody></table></table-wrap><fig position="float" id="F2" orientation="portrait"><label>Figure 2</label><caption><p>Risk of bias graph for included RCTs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpubh-10-829176-g0002.jpg"/></fig><fig position="float" id="F3" orientation="portrait"><label>Figure 3</label><caption><p>Risk of bias summary for included RCTs.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fpubh-10-829176-g0003.jpg"/></fig></sec><sec><title>Safety of COVID-19 Vaccines</title><p>A total of six RCTs (<xref rid="B33" ref-type="bibr">33</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>) evaluated possible adverse reactions after the first and second doses. Only four RCTs (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B36" ref-type="bibr">36</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>) provided data on total adverse reactions, while all six RCTs reported the occurrence of specific adverse reactions after vaccination. Walter et al. did not provide the exact number of participants in the placebo group in the safety analysis. By reading the original article (<xref rid="B35" ref-type="bibr">35</xref>), we only know that there were 748 or 749 children in the placebo group after the first dose, and 740 or 741 children in the placebo group after the second dose. Nevertheless, after data analysis, it was found that the effect of small changes in this data on the results was largely negligible. Therefore, we still included this RCT.</p><p>The data showed that the risk of unsolicited (RR 1.21, 95%CI 1.07&#8211;1.36, <italic toggle="yes">P</italic> = 0.002; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 1</xref>, <xref rid="T2" ref-type="table">Table 2</xref>) adverse reactions was significantly higher in the vaccine group than in the control group, within 28 or 30 days after the whole vaccination procedure. However, for severe (RR 2.35, 95%CI 0.78&#8211;7.03, <italic toggle="yes">P</italic> = 0.13), and even life-threatening (RR 1.00, 95%CI 0.06&#8211;15.94, <italic toggle="yes">P</italic> = 1.00) unsolicited adverse reactions, there was no significant difference between the two groups. No case reports of death, multisystem inflammatory syndrome in children (MIS-C), myocarditis, or pericarditis disease were found in any individual RCT.</p><table-wrap position="float" id="T2" orientation="portrait"><label>Table 2</label><caption><p>Overall adverse reactions and unsolicited adverse reactions within 28 or 30 days after whole vaccination procedure in inactivated vaccine group vs. control group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">
<bold>No. of studies</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>RR (95% CI)</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>I2</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>P</bold>
</italic>
<bold>-value</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Overall adverse reactions within 28 or 30 days after whole vaccination procedure</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.59 [1.26, 2.01]</td><td valign="top" align="center" rowspan="1" colspan="1">77</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN1" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Unsolicited adverse reactions within 28 or 30 days after whole vaccination procedure</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Overall</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">1.21 [1.07, 1.36]</td><td valign="top" align="center" rowspan="1" colspan="1">14</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN1" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Related to study vaccination</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.96 [1.59, 2.41]</td><td valign="top" align="center" rowspan="1" colspan="1">20</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN1" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Severe</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">2.35 [0.78, 7.03]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Life-threatening</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.00 [0.06, 15.94]</td><td valign="top" align="center" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Serious</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.63 [0.45, 5.88]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Medically-attended</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0.96 [0.74, 1.25]</td><td valign="top" align="center" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Leading to discontinuation</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">2.99 [0.36, 24.93]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr></tbody></table><table-wrap-foot><fn id="TN1"><label>*</label><p><italic toggle="yes">P &lt; 0.05</italic>.</p></fn></table-wrap-foot></table-wrap><sec><title>Adverse Reactions to Different Inoculation Doses</title><p>Subgroup analyses of adverse reactions after different number of inoculations were performed. The data showed that the risk of adverse events was statistically higher in the vaccine group than in the control group after the first (RR 1.49, 95%CI 1.43&#8211;1.55, <italic toggle="yes">P</italic> &lt; 0.00001; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 2</xref>, <xref rid="T3" ref-type="table">Table 3</xref>) and second doses (RR 1.76, 95%CI 1.67&#8211;1.85, <italic toggle="yes">P</italic> &lt; 0.00001; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 2</xref>, <xref rid="T3" ref-type="table">Table 3</xref>), but no significant differences were found between the first and second dose groups (RR 1.00, 95%CI 0.99&#8211;1.02, <italic toggle="yes">P</italic> = 0.60; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 3</xref>, <xref rid="T4" ref-type="table">Table 4</xref>). Only one RCT (<xref rid="B37" ref-type="bibr">37</xref>) assessed possible local (RR 1.86, 95%CI 0.55&#8211;6.30, <italic toggle="yes">P</italic> = 0.32; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 2</xref>, <xref rid="T3" ref-type="table">Table 3</xref>) and systemic (RR 2.30, 95%CI 0.69&#8211;7.64, <italic toggle="yes">P</italic> = 0.17; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 2</xref>, <xref rid="T3" ref-type="table">Table 3</xref>) adverse reactions after the third dose, and showed no significant difference between the two groups.</p><table-wrap position="float" id="T3" orientation="portrait"><label>Table 3</label><caption><p>Total adverse reactions in vaccination group vs. control group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">
<bold>No. of studies</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>RR (95% CI)</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>I2</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>P</bold>
</italic>
<bold>-value</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">After dose 1</td><td valign="top" align="left" rowspan="1" colspan="1">Total adverse reactions</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.49 [1.43, 1.55]</td><td valign="top" align="left" rowspan="1" colspan="1">70</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN2" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Local adverse reactions</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">2.60 [2.42, 2.80]</td><td valign="top" align="left" rowspan="1" colspan="1">47</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN2" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Systemic adverse reactions</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.26 [1.19, 1.33]</td><td valign="top" align="left" rowspan="1" colspan="1">68</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN2" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">After dose 2</td><td valign="top" align="left" rowspan="1" colspan="1">Total adverse reactions</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.76 [1.67, 1.85]</td><td valign="top" align="left" rowspan="1" colspan="1">60</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN2" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Local adverse reactions</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">2.89 [2.67, 3.14]</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN2" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Systemic adverse reactions</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.88 [1.77, 2.01]</td><td valign="top" align="left" rowspan="1" colspan="1">29</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN2" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">After dose 3</td><td valign="top" align="left" rowspan="1" colspan="1">Total adverse reactions</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">/</td><td valign="top" align="left" rowspan="1" colspan="1">/</td><td valign="top" align="center" rowspan="1" colspan="1">/</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Local adverse reactions</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1.86 [0.55, 6.30]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Systemic adverse reactions</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">2.30 [0.69, 7.64]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr></tbody></table><table-wrap-foot><fn id="TN2"><label>*</label><p><italic toggle="yes">P &lt; 0.05</italic>.</p></fn></table-wrap-foot></table-wrap><table-wrap position="float" id="T4" orientation="portrait"><label>Table 4</label><caption><p>Total and specific reactions in vaccination group after dose 1 vs. after dose 2.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">
<bold>No. of studies</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>RR (95% CI)</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>I2</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>P</bold>
</italic>
<bold>-value</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Overall</bold>
</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Total adverse reactions</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.00 [0.99, 1.02]</td><td valign="top" align="left" rowspan="1" colspan="1">90</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Local adverse reactions</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.02 [1.00, 1.04]</td><td valign="top" align="left" rowspan="1" colspan="1">82</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN3" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Systemic adverse reactions</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">0.83 [0.81, 0.86]</td><td valign="top" align="left" rowspan="1" colspan="1">96</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN3" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Overall</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">0.73 [0.71, 0.74]</td><td valign="top" align="left" rowspan="1" colspan="1">97</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Local pain</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">1.02 [1.00, 1.04]</td><td valign="top" align="left" rowspan="1" colspan="1">73</td><td valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> = 0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Erythema/ Redness</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">0.70 [0.62, 0.79]</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN3" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Induration</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">2.00 [0.18, 21.71]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pruritus/ Itch</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.15 [0.39, 3.41]</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Swelling</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">0.79 [0.70, 0.89]</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN3" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Axillary Swelling</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1.11 [1.00, 1.23]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> = 0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fever</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">0.44 [0.37, 0.53]</td><td valign="top" align="left" rowspan="1" colspan="1">95</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN3" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Cough</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.76 [0.99, 3.12]</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1"><italic toggle="yes">P</italic> = 0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Oropharyngeal pain</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">3.00 [0.32, 28.35]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Headache</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">0.65 [0.62, 0.69]</td><td valign="top" align="left" rowspan="1" colspan="1">65</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN3" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Fatigue</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">0.72 [0.69, 0.76]</td><td valign="top" align="left" rowspan="1" colspan="1">39</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN3" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Myalgia</td><td valign="top" align="center" rowspan="1" colspan="1">6</td><td valign="top" align="center" rowspan="1" colspan="1">0.59 [0.55, 0.64]</td><td valign="top" align="left" rowspan="1" colspan="1">39</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN3" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Arthralgia</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">0.52 [0.47, 0.58]</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN3" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nausea/ vomiting</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0.47 [0.42, 0.54]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN3" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Nausea</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.24 [0.49, 3.11]</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Vomiting</td><td valign="top" align="center" rowspan="1" colspan="1">5</td><td valign="top" align="center" rowspan="1" colspan="1">1.26 [0.58, 2.78]</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Diarrhea</td><td valign="top" align="center" rowspan="1" colspan="1">4</td><td valign="top" align="center" rowspan="1" colspan="1">1.45 [0.72, 2.94]</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Anorexia</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.81 [0.68, 4.83]</td><td valign="top" align="left" rowspan="1" colspan="1">32</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Chills</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">0.44 [0.40, 0.48]</td><td valign="top" align="left" rowspan="1" colspan="1">41</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN3" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Pruritus (systemic adverse reaction)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">3.00 [0.12, 72.77]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Acute allergic reaction/ Hypersensitivity</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0.33 [0.01, 8.13]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Abnormal skin and mucosa</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">2.92 [0.31, 28.00]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Dysphagia</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0.33 [0.01, 8.09]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr></tbody></table><table-wrap-foot><fn id="TN3"><label>*</label><p><italic toggle="yes">P &lt; 0.05</italic>.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Adverse Reactions to Different COVID-19 Vaccines</title><p>Considering the relatively high statistical heterogeneity in the above analysis (<italic toggle="yes">I</italic><sup>2</sup> from 8 to 70%), we further performed subgroup analyses according to different vaccine types. The data showed a significantly increased risk of total, local, and systemic adverse reactions after vaccination both in the mRNA vaccine group and in the adenovirus vector vaccine group, however, in the inactivated vaccine group, only the risk of local reactions after initial vaccination was significantly higher than in the control group (RR 6.34, 95%CI 1.54&#8211;26.10, <italic toggle="yes">P</italic> = 0.01; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 4</xref>, <xref rid="T5" ref-type="table">Table 5</xref>).</p><table-wrap position="float" id="T5" orientation="portrait"><label>Table 5</label><caption><p>Adverse reactions among vaccination group vs. control group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">
<bold>No. of studies</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>RR (95% CI)</bold>
</th><th valign="top" align="left" rowspan="1" colspan="1">
<bold>I2</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>P</bold>
</italic>
<bold>-value</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" colspan="6" rowspan="1">
<bold>Total adverse reactions</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">After dose 1</td><td valign="top" align="left" rowspan="1" colspan="1">Overall</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.49 [1.43, 1.55]</td><td valign="top" align="left" rowspan="1" colspan="1">70</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">mRNA vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1.47 [1.41, 1.54]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1.27 [0.76, 2.13]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Vectored vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">3.44 [1.78, 6.65]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">After dose 2</td><td valign="top" align="left" rowspan="1" colspan="1">Overall</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.76 [1.67, 1.85]</td><td valign="top" align="left" rowspan="1" colspan="1">60</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">mRNA vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1.74 [1.66, 1.83]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1.83 [0.90, 3.72]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Vectored vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">8.25 [2.06, 33.00]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">After dose 3</td><td valign="top" align="left" rowspan="1" colspan="1">Overall</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">/</td><td valign="top" align="left" rowspan="1" colspan="1">/</td><td valign="top" align="center" rowspan="1" colspan="1">/</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">mRNA vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">/</td><td valign="top" align="left" rowspan="1" colspan="1">/</td><td valign="top" align="center" rowspan="1" colspan="1">/</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">/</td><td valign="top" align="left" rowspan="1" colspan="1">/</td><td valign="top" align="center" rowspan="1" colspan="1">/</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Vectored vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">/</td><td valign="top" align="left" rowspan="1" colspan="1">/</td><td valign="top" align="center" rowspan="1" colspan="1">/</td></tr><tr><td valign="top" align="left" colspan="6" rowspan="1">
<bold>Local adverse reactions</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">After dose 1</td><td valign="top" align="left" rowspan="1" colspan="1">Overall</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">2.60 [2.42, 2.80]</td><td valign="top" align="left" rowspan="1" colspan="1">47</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">mRNA vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">2.56 [2.38, 2.76]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">6.34 [1.54, 26.10]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Vectored vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">6.00 [1.94, 18.53]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">After dose 2</td><td valign="top" align="left" rowspan="1" colspan="1">Overall</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">2.89 [2.67, 3.14]</td><td valign="top" align="left" rowspan="1" colspan="1">8</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">mRNA vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">2.86 [2.64, 3.10]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">4.29 [1.03, 17.96]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">P=0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Vectored vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">19.69 [1.21, 319.62]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">After dose 3</td><td valign="top" align="left" rowspan="1" colspan="1">Overall</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1.86 [0.55, 6.30]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">mRNA vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">/</td><td valign="top" align="left" rowspan="1" colspan="1">/</td><td valign="top" align="center" rowspan="1" colspan="1">/</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1.86 [0.55, 6.30]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Vectored vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">/</td><td valign="top" align="left" rowspan="1" colspan="1">/</td><td valign="top" align="center" rowspan="1" colspan="1">/</td></tr><tr><td valign="top" align="left" colspan="6" rowspan="1">
<bold>Systemic adverse reactions</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">After dose 1</td><td valign="top" align="left" rowspan="1" colspan="1">Overall</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.26 [1.19, 1.33]</td><td valign="top" align="left" rowspan="1" colspan="1">68</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">mRNA vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1.23 [1.17, 1.31]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1.32 [0.87, 2.00]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Vectored vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">3.70 [1.55, 8.83]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">After dose 2</td><td valign="top" align="left" rowspan="1" colspan="1">Overall</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">1.88 [1.77, 2.01]</td><td valign="top" align="left" rowspan="1" colspan="1">29</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">mRNA vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1.87 [1.76, 1.99]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">1.61 [0.76, 3.40]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Vectored vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">6.00 [1.48, 24.38]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN4" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">After dose 3</td><td valign="top" align="left" rowspan="1" colspan="1">Overall</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">2.30 [0.69, 7.64]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">mRNA vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">/</td><td valign="top" align="left" rowspan="1" colspan="1">/</td><td valign="top" align="center" rowspan="1" colspan="1">/</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Inactivated vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">2.30 [0.69, 7.64]</td><td valign="top" align="left" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Vectored vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">/</td><td valign="top" align="left" rowspan="1" colspan="1">/</td><td valign="top" align="center" rowspan="1" colspan="1">/</td></tr></tbody></table><table-wrap-foot><fn id="TN4"><label>*</label><p><italic toggle="yes">P &lt; 0.05</italic>.</p></fn></table-wrap-foot></table-wrap><p>Detailed analyses were conducted for specific adverse events after vaccination. In the mRNA vaccine group, the risk of adverse reactions such as pain, swelling, and fever were significantly higher, both after initial vaccination and booster vaccination (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 5</xref>, <xref rid="SM1" ref-type="supplementary-material">Supplementary Table 1</xref>). In the inactivated vaccine group, only the risk of local pain was significantly higher, and the risk of all other known adverse reactions was not significantly different compared with the control group (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 6</xref>, <xref rid="SM1" ref-type="supplementary-material">Supplementary Table 1</xref>). For the adenovirus vector vaccine, there was no significant difference in the risk of adverse reactions compared with placebo, except for a significantly higher risk of local pain (RR 5.67, 95%CI 1.83&#8211;17.55, <italic toggle="yes">P</italic> = 0.003; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 7</xref>, <xref rid="SM1" ref-type="supplementary-material">Supplementary Table 1</xref>) and fever after (RR 7.00, 95%CI 1.74&#8211;28.21, <italic toggle="yes">P</italic> = 0.006; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 7</xref>, <xref rid="SM1" ref-type="supplementary-material">Supplementary Table 1</xref>) the first dose. After pooling all available data on specific reactions, the risk was significantly higher in all vaccine groups than in the control group, but relatively lower in the inactivated vaccine group, both after initial vaccination (RR 1.40, 95% CI 1.04&#8211;1.90, <italic toggle="yes">p</italic> = 0.03) and after booster vaccination (RR 1.84, 95% CI 1.20&#8211;2.81, <italic toggle="yes">p</italic> = 0.005) (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table 1</xref>).</p></sec><sec><title>Adverse Reactions in Different Age Groups</title><p>When subgroup analysis was performed according to different vaccine types, the data showed that heterogeneity remained generally high in the mRNA vaccine group, but lower heterogeneity could be found in most subgroups after removing the RCT study by Walter et al. (<xref rid="B35" ref-type="bibr">35</xref>). Considering that the RCT by Walter et al. targeted younger children aged 5&#8211;11 years, whereas the other two RCTs studying mRNA vaccines (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B34" ref-type="bibr">34</xref>) were conducted in children and adolescents aged 12 years and older, we decided to perform further subgroup analyses for specific adverse reactions depending on the different ages of mRNA vaccine recipients (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 8</xref>, <xref rid="SM1" ref-type="supplementary-material">Supplementary Table 2</xref>). For older children aged 12&#8211;17 years, the risk of all adverse reactions after vaccination was significantly higher, except for systemic reactions such as vomiting and diarrhea. As for younger children aged 5&#8211;11 years, the risk of headache (RR 0.45, 95%CI 0.26&#8211;0.80, <italic toggle="yes">P</italic> = 0.007) and fatigue (RR 0.54, 95%CI 0.34&#8211;0.88, <italic toggle="yes">P</italic> = 0.01) after the first dose as well as the risk of diarrhea (RR 0.10, 95%CI 0.03&#8211;0.36, <italic toggle="yes">P</italic> = 0.0003) after booster vaccination were even significantly lower; but for other adverse reactions, there was no statistical difference between the two groups.</p><p>Overall, the risk of various adverse reactions after mRNA vaccination appears to be higher in older children aged 12&#8211;17 years than in younger children aged 5&#8211;11 years. Considering that both Frenck et al. (<xref rid="B34" ref-type="bibr">34</xref>) and Walter et al. (<xref rid="B35" ref-type="bibr">35</xref>) chose the mRNA-1273 vaccine as the intervention, we decided to directly compare the occurrence of various adverse reactions following mRNA-1273 vaccination in older and younger children (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 9</xref>, <xref rid="T6" ref-type="table">Table 6</xref>). The data showed a significantly higher risk of various adverse reactions in participants aged 12&#8211;15 years, both after the initial (RR 1.40, 95%CI 1.21&#8211;1.62, <italic toggle="yes">P</italic> &lt; 0.00001) and the booster (RR 2.04, 95%CI 1.75&#8211;2.38, <italic toggle="yes">P</italic> &lt; 0.00001) vaccination, suggesting that the mRNA-1273 vaccine may have a greater safety profile in young children aged 5&#8211;11 years.</p><table-wrap position="float" id="T6" orientation="portrait"><label>Table 6</label><caption><p>Specific adverse reactions in mRNA vaccine recipients aged &#8805;12 years vs. &lt;12 years.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">
<bold>No. of studies</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>RR (95% CI)</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>I2</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>P</bold>
</italic>
<bold>-value</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>After dose 1</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Overall</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.40 [1.21, 1.62]</td><td valign="top" align="center" rowspan="1" colspan="1">71</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN5" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Local pain</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">2.09 [1.56, 2.81]</td><td valign="top" align="center" rowspan="1" colspan="1">93</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN5" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Erythema or Redness</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.77 [0.77, 4.03]</td><td valign="top" align="center" rowspan="1" colspan="1">45</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Swelling</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">2.72 [0.95, 7.74]</td><td valign="top" align="center" rowspan="1" colspan="1">26</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Fever</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">5.12 [1.25, 21.01]</td><td valign="top" align="center" rowspan="1" colspan="1">36</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN5" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Headache</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.04 [0.75, 1.43]</td><td valign="top" align="center" rowspan="1" colspan="1">92</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Fatigue</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.00 [0.75, 1.34]</td><td valign="top" align="center" rowspan="1" colspan="1">90</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Myalgia</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.34 [0.78, 2.29]</td><td valign="top" align="center" rowspan="1" colspan="1">67</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Arthralgia</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0.87 [0.41, 1.85]</td><td valign="top" align="center" rowspan="1" colspan="1">69</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Vomiting</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.85 [0.38, 9.07]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Diarrhea</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0.97 [0.44, 2.12]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Chills</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.87 [1.05, 3.36]</td><td valign="top" align="center" rowspan="1" colspan="1">82</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN5" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>After dose 2</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Overall</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">2.04 [1.75, 2.38]</td><td valign="top" align="center" rowspan="1" colspan="1">77</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN5" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Local pain</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">2.21 [1.62, 3.02]</td><td valign="top" align="center" rowspan="1" colspan="1">93</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN5" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Erythema or Redness</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">2.28 [0.95, 5.48]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Swelling</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">2.97 [1.03, 8.57]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN5" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Fever</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">10.52 [2.68, 41.29]</td><td valign="top" align="center" rowspan="1" colspan="1">32</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN5" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Headache</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.69 [1.20, 2.38]</td><td valign="top" align="center" rowspan="1" colspan="1">92</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN5" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Fatigue</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.60 [1.16, 2.22]</td><td valign="top" align="center" rowspan="1" colspan="1">92</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN5" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Myalgia</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">2.30 [1.31, 4.01]</td><td valign="top" align="center" rowspan="1" colspan="1">84</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN5" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Arthralgia</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.86 [0.88, 3.92]</td><td valign="top" align="center" rowspan="1" colspan="1">74</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Vomiting</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.85 [0.38, 9.05]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Diarrhea</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0.53 [0.25, 1.13]</td><td valign="top" align="center" rowspan="1" colspan="1">89</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1">Chills</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">3.93 [2.11, 7.33]</td><td valign="top" align="center" rowspan="1" colspan="1">80</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN5" ref-type="table-fn"><sup>*</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="TN5"><label>*</label><p><italic toggle="yes">P &lt; 0.05</italic>.</p></fn></table-wrap-foot></table-wrap><p>Two RCTs on inactivated vaccines (CoronaVac (<xref rid="B36" ref-type="bibr">36</xref>), BBIBP-COV (<xref rid="B37" ref-type="bibr">37</xref>)) both reported total adverse reactions in children of different ages within 28 days after the whole vaccination procedure, so subgroup analysis was performed according to the age of the participants (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 10</xref>, <xref rid="T7" ref-type="table">Table 7</xref>). The data showed that the risk of adverse reactions was higher in all inactivated vaccine subgroups than in all control groups, especially in the 6-11/12 age group (RR 2.41, 95%CI 1.37&#8211;4.23, <italic toggle="yes">P</italic> = 0.002); however, the difference was not statistically significant in the 3&#8211;5 age group (RR 1.15, 95%CI 0.81&#8211;1.64, <italic toggle="yes">P</italic> = 0.43). Notably, participants in one RCT study (<xref rid="B36" ref-type="bibr">36</xref>) received a total of 2 doses of vaccine, whereas participants in the other RCT study (<xref rid="B37" ref-type="bibr">37</xref>) received a total of 3 doses of vaccine. However, it was not possible to specifically analyze the safety of inactivated vaccines after a single dose, because Han et al. (<xref rid="B36" ref-type="bibr">36</xref>) did not provide information on adverse reactions within 28 days after a single dose. In addition, there were minor differences in the grouping methods of the two RCTs, with one (<xref rid="B36" ref-type="bibr">36</xref>) grouping vaccinees into age groups of 3&#8211;5, 6&#8211;11, and 12&#8211;17 years, while the other (<xref rid="B37" ref-type="bibr">37</xref>) grouping participants into age groups of 3&#8211;5, 6&#8211;12, and 13&#8211;17 years. Overall, the risk of adverse reactions following inactivated vaccination was more noteworthy in older children than in younger children, which is generally consistent with the results of subgroup analyses of mRNA vaccines.</p><table-wrap position="float" id="T7" orientation="portrait"><label>Table 7</label><caption><p>Overall adverse reactions within 28 days after whole vaccination procedure in inactivated vaccine group of different ages vs. control group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">
<bold>No. of studies</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>RR (95% CI)</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>I2</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>P</bold>
</italic>
<bold>-value</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">Overall adverse reactions within 28 days after whole vaccination procedure</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.60 [1.27, 2.01]</td><td valign="top" align="center" rowspan="1" colspan="1">57</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN6" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3&#8211;5 years old</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.15 [0.81, 1.64]</td><td valign="top" align="center" rowspan="1" colspan="1">28</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6&#8211;11/12 years old</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">2.41 [1.37, 4.23]</td><td valign="top" align="center" rowspan="1" colspan="1">83</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN6" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12/13&#8211;17 years old</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">1.71 [1.19, 2.46]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN6" ref-type="table-fn"><sup>*</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="TN6"><label>*</label><p><italic toggle="yes">P &lt; 0.05</italic>.</p></fn></table-wrap-foot></table-wrap><p>Since only one RCT (<xref rid="B38" ref-type="bibr">38</xref>) chose the adenovirus vector vaccine as an intervention, and no data were available for different age groups, further subgroup analysis could not be performed for the adenovirus vector vaccine.</p></sec><sec><title>Adverse Reactions in Different Doses of Vaccines</title><p>Two RCTs (<xref rid="B36" ref-type="bibr">36</xref>, <xref rid="B37" ref-type="bibr">37</xref>) provided information on recipients aged 3&#8211;17 years after receiving different doses of inactivated vaccine, but subgroup analyses failed to be performed on this basis because the vaccine doses differed in the two RCTs. However, data from both RCTs suggested acceptable safety and tolerability profiles for various doses of inactivated vaccines.</p></sec></sec><sec><title>Immunogenicity</title><sec><title>Humoral Immune Responses</title><p>Three RCTs (<xref rid="B36" ref-type="bibr">36</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>) provided data on seroconversion, and the data showed that the seroconversion after inoculation was significant, especially after the second dose (RR 144.80, 95%CI 44.97&#8211;466.24, <italic toggle="yes">P</italic> &lt; 0.00001; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 11</xref>, <xref rid="T8" ref-type="table">Table 8</xref>). Notably, although participants reported by Xia et al. (<xref rid="B37" ref-type="bibr">37</xref>) received a total of three doses of adenoviral vector vaccine, their serological response rate had reached 100% at day 56 (28 days after the second dose).</p><table-wrap position="float" id="T8" orientation="portrait"><label>Table 8</label><caption><p>Seroconversion rate in vaccine group vs. control group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">
<bold>No. of studies</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>RR (95% CI)</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>I2</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>P</bold>
</italic>
<bold>-value</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" colspan="5" rowspan="1">
<bold>Pseudovirus neutralizing antibody</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">28 days after Dose 1</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">77.99 [28.40, 214.14]</td><td valign="top" align="center" rowspan="1" colspan="1">82</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN7" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">28 days after Dose 2</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">144.80 [44.97, 466.24]</td><td valign="top" align="center" rowspan="1" colspan="1">73</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN7" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Neutralizing antibody 28 days after Dose 2</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">118.74 [38.67, 364.63]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN7" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">3-5 years old</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">110.57 [15.87, 770.57]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN7" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">6&#8211;11/12 years old</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">124.37 [17.79, 869.21]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN7" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">12/ 13&#8211;17 years old</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">121.28 [17.36, 847.06]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN7" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" colspan="5" rowspan="1">
<bold>RBD&#8211;binding enzyme-linked immunosorbent assay antibody</bold>
</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">28 days after Dose 1</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">99.48 [6.31, 1569.12]</td><td valign="top" align="center" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN7" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">56 days after Dose 1 (Before Dose 2)</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">98.47 [6.24, 1553.30]</td><td valign="top" align="center" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN7" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">28 days after Dose 2</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">101.50 [6.44, 1600.76]</td><td valign="top" align="center" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN7" ref-type="table-fn"><sup>*</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="TN7"><label>*</label><p><italic toggle="yes">P &lt; 0.05</italic>.</p></fn></table-wrap-foot></table-wrap><p>In addition, given that Han et al. (<xref rid="B36" ref-type="bibr">36</xref>) and Xia et al. (<xref rid="B37" ref-type="bibr">37</xref>) both provided seroconversions for each age group at 28 days post-vaccination, a subgroup analysis was performed accordingly. The data showed a significant humoral immune response to SARS-CoV-2 after inactivated vaccination in all age groups, but the response appears to be relatively low in children aged 3&#8211;5 years (RR 110.57, 95%CI 15.87&#8211;770.57, <italic toggle="yes">P</italic> &lt; 0.00001; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 11</xref>, <xref rid="T8" ref-type="table">Table 8</xref>). Moreover, Han et al. (<xref rid="B36" ref-type="bibr">36</xref>) and Xia et al. (<xref rid="B37" ref-type="bibr">37</xref>) also provided data for different doses, which may suggest dose-dependent immunogenicity. Han et al. (<xref rid="B36" ref-type="bibr">36</xref>) indicated that the neutralizing antibody titer induced by the 3.0 &#956;g dose group was obviously higher than that of the 1.5 &#956;g dose group after boost vaccination (<italic toggle="yes">P</italic> &lt; 0.05). Similarly, it was reported by Xia et al. (<xref rid="B37" ref-type="bibr">37</xref>) that the 4 and 8 &#956;g dose groups elicited significantly higher antibody responses compared with the 2 &#956;g dose group (<italic toggle="yes">P</italic> &lt; 0.05).</p><p>Three other RCTs (<xref rid="B33" ref-type="bibr">33</xref>&#8211;<xref rid="B35" ref-type="bibr">35</xref>) with mRNA vaccine as the intervention compared immune responses 1 month after booster vaccination in vaccinees and young adults (16 or 18 years of age and older), and assessed non-inferiority by calculating the geometric mean ratio (GMR) with its 95% confidence interval. Ali et al. (<xref rid="B33" ref-type="bibr">33</xref>) reported the GMT of 1401.7 (95% CI: 1276.3, 1539.4) in adolescents aged 12&#8211;17 years, with a neutralizing antibody GMR of 1.08 (95% CI: 0.94 to 1.24) relative to young adults aged 18 to 25 years, meeting the non-inferiority criterion (i.e., lower limit of the two-sided 95% confidence interval &gt; 0.67). As reported by Frenck et al. (<xref rid="B34" ref-type="bibr">34</xref>) and Walter et al. (<xref rid="B35" ref-type="bibr">35</xref>), the GMRs of neutralizing antibodies in adolescents aged 12 to 15 years and children aged 5&#8211;11 years to young adults aged 16 to 25 years were respectively 1.76 (95% CI: 1.47&#8211;2.10), and 1.04 (95% CI: 0.93&#8211;1.18), which met the criteria of non-inferiority as well. In particular, the immune response to BNT162b2 Covid-19 vaccine might be greater in adolescents aged 12 to 15 years than in young adults aged 16 to 25 years, because the lower limit of the two-sided 95% confidence interval for the GMR is &gt;1.</p><p>There were also two RCT studies (<xref rid="B33" ref-type="bibr">33</xref>, <xref rid="B38" ref-type="bibr">38</xref>) evaluating the receptor binding domain (RBD)-binding ELISA antibody. The results of Ali et al. (<xref rid="B33" ref-type="bibr">33</xref>) showed a GMR of 1.09 (95% CI: 0.94&#8211;1.26) for RBD-binding ELISA antibodies in adolescents aged 12&#8211;17 years relative to young adults aged 16&#8211;25 years, while in the trial of Zhu et al. (<xref rid="B38" ref-type="bibr">38</xref>), the seroconversion rate of RBD-binding antibodies in the vaccine group reached 98%(RR 99.48, 95%CI 6.31&#8211;1,569.12, <italic toggle="yes">P</italic> = 0.001) and 100%(RR 101.50, 95%CI 6.44&#8211;1,600.76, <italic toggle="yes">P</italic> = 0.001) at day 28 after initial and booster vaccination, respectively (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 11</xref>, <xref rid="T8" ref-type="table">Table 8</xref>).</p></sec><sec><title>Cellular Immune Responses</title><p>There was only one RCT (<xref rid="B38" ref-type="bibr">38</xref>) evaluating the potential of vaccines to induce specific cellular responses. It was reported that significant specific T-cell responses, particularly Th 1 cell responses, were induced after initial adenoviral vector vaccination, but the intensity of immunity appeared to diminish after booster vaccination.</p></sec></sec><sec><title>Efficacy</title><p>Three RCTs (<xref rid="B33" ref-type="bibr">33</xref>&#8211;<xref rid="B35" ref-type="bibr">35</xref>) with mRNA vaccine as an intervention assessed vaccine efficacy, which was at 100.0% (95% CI: 28.9%-NE%), 100% (95% CI: 75.3%&#8211;100%), and 90.7% (95% CI: 67.4%&#8211;98.3%), respectively. Both types of mRNA vaccines provided satisfactory prevention against COVID-19, especially the BNT162b2 Covid-19 vaccine for adolescents aged 12 years and older (RR 0.03, 95%CI 0.00&#8211;0.44; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 12</xref>, <xref rid="T9" ref-type="table">Table 9</xref>) (<xref rid="B34" ref-type="bibr">34</xref>). Other RCT studies (<xref rid="B36" ref-type="bibr">36</xref>&#8211;<xref rid="B38" ref-type="bibr">38</xref>) with inactivated vaccine or adenovirus vector vaccine as interventions did not evaluate the vaccine efficacy.</p><table-wrap position="float" id="T9" orientation="portrait"><label>Table 9</label><caption><p>COVID-19 diagnosed after vaccination in vaccine group vs. control group.</p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1"/><th valign="top" align="center" rowspan="1" colspan="1">
<bold>No. of studies</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>RR (95% CI)</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<bold>I2</bold>
</th><th valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">
<bold>P</bold>
</italic>
<bold>-value</bold>
</th></tr></thead><tbody><tr><td valign="top" align="left" rowspan="1" colspan="1">
<bold>Covid-19 after the vaccination</bold>
</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">0.10 [0.05, 0.21]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN8" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">After dose 1 to before dose 2</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0.25 [0.07, 0.88]</td><td valign="top" align="center" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN8" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">Within 7 days after the second dose</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0.09 [0.01, 1.64]</td><td valign="top" align="center" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&gt;0.05</td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">7 days after second dose</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0.06 [0.02, 0.20]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN8" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">14 days after second dose</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0.07 [0.01, 0.56]</td><td valign="top" align="center" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN8" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1"><bold>Covid-19 after dose</bold> 2</td><td valign="top" align="center" rowspan="1" colspan="1">3</td><td valign="top" align="center" rowspan="1" colspan="1">0.06 [0.02, 0.18]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN8" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">mRNA-1273 vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">1</td><td valign="top" align="center" rowspan="1" colspan="1">0.07 [0.01, 0.56]</td><td valign="top" align="center" rowspan="1" colspan="1">Not applicable</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN8" ref-type="table-fn"><sup>*</sup></xref></td></tr><tr><td valign="top" align="left" rowspan="1" colspan="1">BNT162b2 Covid-19 Vaccine</td><td valign="top" align="center" rowspan="1" colspan="1">2</td><td valign="top" align="center" rowspan="1" colspan="1">0.06 [0.02, 0.20]</td><td valign="top" align="center" rowspan="1" colspan="1">0</td><td valign="top" align="center" rowspan="1" colspan="1">&lt;0.05<xref rid="TN8" ref-type="table-fn"><sup>*</sup></xref></td></tr></tbody></table><table-wrap-foot><fn id="TN8"><label>*</label><p><italic toggle="yes">P &lt; 0.05</italic>.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>Sensitivity Analysis and Publication Bias</title><p>Through detailed subgroup analysis, we have tried to minimize the effect of heterogeneity on our results. However, when performing sensitivity analyses, we still found that the heterogeneity of pooled effects for certain outcomes may change substantially after removing individual RCT. Although the changes barely affect our conclusions, it still suggests that the results are not robust enough and need to be viewed with caution. As suggested by the Cochrane Handbook (<xref rid="B29" ref-type="bibr">29</xref>), it is well known that assessing publication bias with funnel plots is not reliable when fewer than 10 studies were included (<xref rid="B32" ref-type="bibr">32</xref>). It was only a total of 6 RCTs that were included in this meta-analysis, and there were essentially only 3 or fewer papers available for specific outcome indicators. Therefore, given the limited number of available literature, we did not assess the publication bias.</p></sec><sec><title>Grading of Evidence Quality</title><p>As shown in the <xref rid="SM1" ref-type="supplementary-material">Supplementary Tables 3</xref>&#8211;<xref rid="SM1" ref-type="supplementary-material">6</xref>, we assessed the quality of the primary outcomes. Overall, the quality of evidence for most outcomes was moderate and high, with inconsistency as the main downgrading factor.</p></sec></sec><sec sec-type="discussion" id="s4"><title>Discussion</title><p>The risk of various adverse reactions, mainly including local pain, swelling and fever, was increased to varying degrees after different types of vaccination, but they were generally mild and not fatal. There was insufficient evidence to attribute the reported severe adverse events exclusively to vaccination. It was inactivated vaccines that had a higher safety profile compared with mRNA vaccines and adenoviral vector vaccines, and data are available to support the safety and tolerability of inactivated vaccines at different doses. Besides, the risk of adverse reactions occurring after the first two doses was significantly increased, but no significant differences were found between the prime and boost vaccination groups. Relatively speaking, the third dose of vaccine might be safer for vaccinees. Moreover, there were subtle differences in the risk of adverse reactions among different age groups. For older vaccine recipients, adverse reactions caused by mRNA vaccine and inactivated vaccine warrant further attention.</p><p>In addition, good immunogenicity could be observed for all vaccine types and, in particular, dose-level-dependent immunogenicity was found in the inactivated vaccine group. The immunogenicity of vaccines varies slightly among age groups. Older children over 12 years of age would develop a stronger immune response after vaccination, especially after BNT162b2 Covid-19 vaccine. This difference may be related to the fact that immune function is not yet well developed in young children. Furthermore, although there was no significant difference in the risk of adverse reactions between single-dose and double-dose vaccines, the double-dose regimen was significantly superior to the single-dose schedule in terms of humoral immunogenicity and prophylactic efficacy. However, data from Zhu et al. (<xref rid="B38" ref-type="bibr">38</xref>) showed no further enhancement in the intensity of T-cell immune response after booster vaccination. This result should be viewed with caution due to the limited data on the cellular immune response. What's more, both types of mRNA vaccines have shown satisfactory efficacy in preventing COVID-19, especially the BNT162b2 Covid-19 vaccine applied in adolescents aged 12 years and older.</p><p>In general, in this meta-analysis based on RCTs, the safety, immunogenicity, and efficacy of the COVID-19 vaccines were confirmed to some extent in children and teenagers aged 3 to 17 years, but analyses in younger children under 3 years of age and even in infants were lacking. For different vaccine types, inactivated vaccines had better safety profiles significantly; for different injection regimens, double-dose vaccination induced a stronger humoral immune response and produced better prophylactic effects; for different age groups of vaccinees, the vaccine has better immunogenicity in older children, accompanied by a higher risk of adverse reactions; for different doses of inactivated vaccine, there were no significant differences in adverse reactions among different dose groups, but the humoral immune response was more pronounced in the high dose group. If possible, individualized vaccination programs can be considered. Countries can administer the most appropriate COVID-19 vaccine to children and adolescents of different ages in a variety of health conditions, depending on local circumstances.</p><p>In addition to six included RCTs, a comprehensive search identified three relevant trials (<xref rid="B20" ref-type="bibr">20</xref>, <xref rid="B39" ref-type="bibr">39</xref>, <xref rid="B40" ref-type="bibr">40</xref>) that included adolescents, all of which confirmed good safety and immunogenicity of the vaccine in this age group but were not included in the review because no information was specifically provided for specific age group. Notably, Thomas et al. (<xref rid="B40" ref-type="bibr">40</xref>) followed the subjects for 6 months and confirmed that the immune efficacy of the BNT162b2 Covid-19 vaccine, although gradually decreasing over time, could still be maintained at a good level.</p><p>To our knowledge, this is the first meta-analysis specifically targeting COVID-19 vaccine recipients under the age of 18 years, which has comprehensively assessed the safety, immunogenicity, and efficacy of COVID-19 vaccines in the population. Previously, Liu et al. published a systematic review (<xref rid="B41" ref-type="bibr">41</xref>) evaluating COVID-19 vaccination in children and adolescents, but that review included only two RCTs and did not perform a quantitative analysis. Moreover, those included in this review are all recently published, high-quality randomized controlled trials, that can provide the strongest evidence to date. In addition, to reduce the effect of heterogeneity, we performed a rigorous subgroup analysis to figure more precise and detailed results. However, there are some limitations as well. First of all, we only included a limited number of RCTs, including only three types of COVID-19 vaccines (the mRNA vaccine, inactivated vaccine, and adenovirus vector vaccine), and lacked data on younger children under 3 years of age or even infants, as well as long-term follow-up data. Besides, the RCT (<xref rid="B38" ref-type="bibr">38</xref>) with adenoviral vector vaccine as an intervention was a small-sample study, so the data provided may be overridden by other large-sample studies. Although this possibility has been substantially reduced by detailed subgroup analysis, the small sample size may still limit the statistical validity of this trial. Furthermore, for the cellular immune response after vaccination, only one RCT (<xref rid="B38" ref-type="bibr">38</xref>) provided relevant data. In addition, although methodological heterogeneity and clinical heterogeneity were well controlled, statistical heterogeneity could not be ignored. Despite the implementation of careful subgroup analyses, high statistical heterogeneity could still be found in some subgroups, which may be related to potential factors such as geographic region, population ethnicity, and vaccine dose.</p><p>Regarding vaccination of people under 18 years of age, the following issues remain to be urgently addressed.</p><p>To begin with, there is an urgent need to fill the gaps in long-term follow-up data, to assess the duration of immune response after vaccination, and whether vaccines cause long-term adverse outcomes, such as myocarditis. Although the available data (<xref rid="B42" ref-type="bibr">42</xref>) suggested that the incidence and long-term risk of myocarditis caused by the virus itself appeared to be more threatening than that of vaccine-associated myocarditis, which might be self-limiting, we still need stronger evidence to dispel this concern. Besides, recent data (<xref rid="B43" ref-type="bibr">43</xref>) indicates that inactivated vaccination may cause pathophysiological changes in vaccine recipients similar to those in infected individuals, suggesting that careful consideration is needed when vaccinating children, even with inactivated vaccines that appear to be safer, especially for children with underlying disease. What's more, given that MIS-C may be an immune disease associated with SARS-CoV-2 infection, we cannot exclude the possibility that this complication is instead induced after COVID-19 vaccination (<xref rid="B11" ref-type="bibr">11</xref>). Relevant studies are urgently needed to elucidate the mechanism underlying this rare but severe disease (<xref rid="B44" ref-type="bibr">44</xref>).</p><p>Moreover, assessment of children under 3 years of age and even infants is urgently needed on the agenda. As reported (<xref rid="B45" ref-type="bibr">45</xref>), Pfizer may respectively release the results of vaccination trials for children aged 2 to 5 years by the end of 2021, and for children aged 6 months to 2 years in the first quarter of 2022, which, if positive, will greatly facilitate the vaccination process for younger children. Besides, immune protection for this specific group of newborns could be considered starting with pregnant women. Recent studies (<xref rid="B46" ref-type="bibr">46</xref>&#8211;<xref rid="B48" ref-type="bibr">48</xref>) have shown that antibodies can be detected in the placenta or breast milk after vaccination of pregnant or lactating women without a significant increase in adverse fetal or neonatal outcomes, which may suggest an alternative route of immune protection for the fetus or newborn. Higher-level randomized controlled trials are needed to validate this idea in order to ensure maternal and infant safety.</p><p>Furthermore, considering the overall benefits to society, we have to assess whether the benefits of vaccinating children outweigh the burden on overall local epidemic control (<xref rid="B49" ref-type="bibr">49</xref>). In a situation where vaccines are in short supply, it seems more ethical to give priority to immunocompromised populations such as the elderly (<xref rid="B50" ref-type="bibr">50</xref>). Local tailoring may be the solution to this dilemma. However, it was the emergence of the Omicron variant that has reminded us the only a comprehensive vaccination program, including for low-risk populations, will allow us to achieve victory against the epidemic.</p><p>In addition, given the urgency of advancing childhood vaccination, there is a need for a comprehensive assessment of the factors influencing vaccination, particularly those affecting parental intentions. Surveys around the world (<xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>, <xref rid="B51" ref-type="bibr">51</xref>) have shown that distrust in the safety and efficacy of vaccines is an important reason why parents are reluctant to have their children vaccinated, and that most parents are willing to vaccinate their children when the vaccine is safe and reliable. Therefore, high-quality studies assessing the safety and efficacy of the COVID-19 vaccine in younger children appear to be essential to eliminate childhood vaccine hesitancy. Moreover, parental fear of COVID-19 is an important influencing factor in the decision to vaccinate children (<xref rid="B51" ref-type="bibr">51</xref>, <xref rid="B52" ref-type="bibr">52</xref>), stemming not only from the health risks children may face, but also from the risk of family transmission due to children's infection, which may have a negative impact on the family's economic income as well as social activities. Therefore, in order to enhance parents' perception of COVID-19, local governments should proactively provide a platform for scientific communication and share valid data in a timely manner. Furthermore, race, religious affiliation, trust in government agencies, willingness to get vaccinated for themselves, education level, annual income, work environment, mother tongue, and age may all be important factors influencing parent's willingness (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B51" ref-type="bibr">51</xref>). As the epidemic progressed, surveys from various countries spurted out, but most were single-center surveys. Surveys may be contradictory from country to country (<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>), and parental attitudes may change as the epidemic evolves. Therefore, in addition to continuing to advance research on vaccines, a systematic review that brings together various influencing factors is highly desirable (<xref rid="B41" ref-type="bibr">41</xref>) and will help us assess the influencing factors that affect parental willingness in different contexts, thus guiding us to take various effective measures to advance the childhood vaccination process for various populations in different regions.</p></sec><sec sec-type="conclusions" id="s5"><title>Conclusions</title><p>In conclusion, our meta-analysis pooled the available randomized controlled trials and confirmed the favorable safety, immunogenicity, and efficacy of COVID-19 vaccines (mRNA-1273 vaccine, BNT162b2 Covid-19 Vaccine, CoronaVac, BBIBP-COV, and Ad5-vectored COVID-19 vaccine) in adolescents and children aged 3&#8211;17 years. Nevertheless, there is still a large gap in trials to confirm the safety and efficacy of different COVID-19 vaccines in people under 18 years of age, especially in younger children under 3 years old and even infants. There is an urgent need to conduct multicenter, large-sample clinical studies of COVID-19 vaccine in younger children with a wider range of vaccine types and longer follow-up periods, to promote global universalization and standardization of childhood vaccination. Given the rapidly changing epidemiological situation and the advancing vaccine research process, this meta-analysis should be updated in time when more data are available.</p></sec><sec sec-type="data-availability" id="s6"><title>Data Availability Statement</title><p>The original contributions presented in the study are included in the article/<xref rid="s9" ref-type="sec">Supplementary Materials</xref>, further inquiries can be directed to the corresponding author.</p></sec><sec id="s7"><title>Author Contributions</title><p>YD and YS conceived and designed the study, performed the data analysis, and prepared the figures and the tables. YD and LC conducted the database search and extracted the data. YD wrote the manuscript. LC and YS revised it critically for important intellectual content. YS is the guarantor. All authors contributed to the article and approved the submitted version.</p></sec><sec sec-type="COI-statement" id="conf1"><title>Conflict of Interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s8"><title>Publisher's Note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec></body><back><sec sec-type="supplementary-material" id="s9"><title>Supplementary Material</title><p>The Supplementary Material for this article can be found online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.frontiersin.org/articles/10.3389/fpubh.2022.829176/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fpubh.2022.829176/full#supplementary-material</ext-link></p><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Data_Sheet_1.ZIP" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec><ref-list><title>References</title><ref id="B1"><label>1.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Trade Organization</collab></person-group>. <source>Coronavirus disease (COVID-19) Weekly Epidemiological Update and Weekly Operational Update</source>. (<year>2021</year>). Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports" ext-link-type="uri">https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports</ext-link> (accessed November 23, 2021).</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>ElBagoury</surname><given-names>M</given-names></name><name name-style="western"><surname>Tolba</surname><given-names>MM</given-names></name><name name-style="western"><surname>Nasser</surname><given-names>HA</given-names></name><name name-style="western"><surname>Jabbar</surname><given-names>A</given-names></name><name name-style="western"><surname>Elagouz</surname><given-names>AM</given-names></name><name name-style="western"><surname>Aktham</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>The find of COVID-19 vaccine: challenges and opportunities</article-title>. <source>J Infect Public Health.</source> (<year>2021</year>) <volume>14</volume>:<fpage>389</fpage>&#8211;<lpage>416</lpage>. <pub-id pub-id-type="doi">10.1016/j.jiph.2020.12.025</pub-id><pub-id pub-id-type="pmid">33647555</pub-id><pub-id pub-id-type="pmcid">PMC7773313</pub-id></mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>World Trade Organization</collab></person-group>. <source>Draft Landscape and Tracker of COVID-19 Candidate Vaccines</source>. (<year>2021</year>). Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines" ext-link-type="uri">https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines</ext-link> (accessed November 19, 2021).</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Centers for Disease Control Prevention</collab></person-group>. <source>CDC Recommends Pediatric COVID-19 Vaccine for Children 5 to 11 Years</source>. (<year>2021</year>). Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/media/releases/2021/s1102-PediatricCOVID-19Vaccine.html" ext-link-type="uri">https://www.cdc.gov/media/releases/2021/s1102-PediatricCOVID-19Vaccine.html</ext-link> (accessed November 10, 2021).</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Anderson</surname><given-names>EJ</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>JD</given-names></name><name name-style="western"><surname>Creech</surname><given-names>CB</given-names></name><name name-style="western"><surname>Frenck</surname><given-names>R</given-names></name><name name-style="western"><surname>Kamidani</surname><given-names>S</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>FM</given-names></name><etal/></person-group>. <article-title>Warp speed for coronavirus disease 2019 (COVID-19) vaccines: why are children stuck in neutral?</article-title><source>Clin Infect Dis.</source> (<year>2021</year>) <volume>73</volume>:<fpage>336</fpage>&#8211;<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1093/cid/ciaa1425</pub-id><pub-id pub-id-type="pmid">32945335</pub-id><pub-id pub-id-type="pmcid">PMC7543330</pub-id></mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>de Souza</surname><given-names>TH</given-names></name><name name-style="western"><surname>Nadal</surname><given-names>JA</given-names></name><name name-style="western"><surname>Nogueira</surname><given-names>RJN</given-names></name><name name-style="western"><surname>Pereira</surname><given-names>RM</given-names></name><name name-style="western"><surname>Brand&#227;o</surname><given-names>MB</given-names></name></person-group>. <article-title>Clinical manifestations of children with COVID-19: a systematic review</article-title>. <source>Pediatr Pulmonol.</source> (<year>2020</year>) <volume>55</volume>:<fpage>1892</fpage>&#8211;<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1002/ppul.24885</pub-id><pub-id pub-id-type="pmid">32492251</pub-id><pub-id pub-id-type="pmcid">PMC7300659</pub-id></mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>P</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N</given-names></name></person-group>. <article-title>Why is COVID-19 less severe in children? a review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections</article-title>. <source>Arch Dis Child.</source> (<year>2020</year>). <pub-id pub-id-type="doi">10.1136/archdischild-2020-320338</pub-id><pub-id pub-id-type="pmid">33262177</pub-id></mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Blanchard-Rohner</surname><given-names>G</given-names></name><name name-style="western"><surname>Didierlaurent</surname><given-names>A</given-names></name><name name-style="western"><surname>Tilmanne</surname><given-names>A</given-names></name><name name-style="western"><surname>Smeesters</surname><given-names>P</given-names></name><name name-style="western"><surname>Marchant</surname><given-names>A</given-names></name></person-group>. <article-title>Pediatric COVID-19: immunopathogenesis, transmission and prevention</article-title>. <source>Vaccines.</source> (<year>2021</year>) <volume>9</volume>:<fpage>1002</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines9091002</pub-id><pub-id pub-id-type="pmid">34579240</pub-id><pub-id pub-id-type="pmcid">PMC8473426</pub-id></mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Feldstein</surname><given-names>LR</given-names></name><name name-style="western"><surname>Rose</surname><given-names>EB</given-names></name><name name-style="western"><surname>Horwitz</surname><given-names>SM</given-names></name><name name-style="western"><surname>Collins</surname><given-names>JP</given-names></name><name name-style="western"><surname>Newhams</surname><given-names>MM</given-names></name><name name-style="western"><surname>Son</surname><given-names>MBF</given-names></name><etal/></person-group>. <article-title>Multisystem inflammatory syndrome in US children and adolescents</article-title>. <source>N Eng J Med.</source> (<year>2020</year>) <volume>383</volume>:<fpage>334</fpage>&#8211;<lpage>46</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2021680</pub-id><pub-id pub-id-type="pmid">32598831</pub-id><pub-id pub-id-type="pmcid">PMC7346765</pub-id></mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Centers for Disease Control Prevention</collab></person-group>. <source>People with Certain Medical Conditions</source>. (<year>2021</year>). Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html" ext-link-type="uri">https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html</ext-link> (accessed November 15, 2021).</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zimmermann</surname><given-names>P</given-names></name><name name-style="western"><surname>Pittet</surname><given-names>LF</given-names></name><name name-style="western"><surname>Finn</surname><given-names>A</given-names></name><name name-style="western"><surname>Pollard</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Curtis</surname><given-names>N</given-names></name></person-group>. <article-title>Should children be vaccinated against COVID-19?</article-title><source>Arch Dis Child.</source> (<year>2021</year>) <volume>107</volume>:<fpage>e1</fpage>. <pub-id pub-id-type="doi">10.1136/archdischild-2021-323040</pub-id><pub-id pub-id-type="pmid">34732388</pub-id></mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Galmiche</surname><given-names>S</given-names></name><name name-style="western"><surname>Charmet</surname><given-names>T</given-names></name><name name-style="western"><surname>Schaeffer</surname><given-names>L</given-names></name><name name-style="western"><surname>Paireau</surname><given-names>J</given-names></name><name name-style="western"><surname>Grant</surname><given-names>R</given-names></name><name name-style="western"><surname>Ch&#233;ny</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Exposures associated with SARS-CoV-2 infection in France: a nationwide online case-control study</article-title>. <source>Lancet Reg Health Eur.</source> (<year>2021</year>) <volume>7</volume>:<fpage>100148</fpage>. <pub-id pub-id-type="doi">10.1016/j.lanepe.2021.100148</pub-id><pub-id pub-id-type="pmid">34124709</pub-id><pub-id pub-id-type="pmcid">PMC8183123</pub-id></mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jing</surname><given-names>QL</given-names></name><name name-style="western"><surname>Liu</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>ZB</given-names></name><name name-style="western"><surname>Fang</surname><given-names>LQ</given-names></name><name name-style="western"><surname>Yuan</surname><given-names>J</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>AR</given-names></name><etal/></person-group>. <article-title>Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study</article-title>. <source>Lancet Infect Dis.</source> (<year>2020</year>) <volume>20</volume>:<fpage>1141</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30471-0</pub-id><pub-id pub-id-type="pmid">32562601</pub-id><pub-id pub-id-type="pmcid">PMC7529929</pub-id></mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Centers for Disease Control Prevention</collab></person-group>. <source>Schools, Child Care, and Colleges</source>. (<year>2021</year>). Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/index.html" ext-link-type="uri">https://www.cdc.gov/coronavirus/2019-ncov/community/schools-childcare/index.html</ext-link> (accessed November 15, 2021).</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cauchemez</surname><given-names>S</given-names></name><name name-style="western"><surname>Bosetti</surname><given-names>P</given-names></name><name name-style="western"><surname>Kiem</surname><given-names>CT</given-names></name><name name-style="western"><surname>Mouro</surname><given-names>V</given-names></name><name name-style="western"><surname>Consoli</surname><given-names>A</given-names></name><name name-style="western"><surname>Fontanet</surname><given-names>A</given-names></name></person-group>. <article-title>Education and mental health: good reasons to vaccinate children</article-title>. <source>Lancet.</source> (<year>2021</year>) <volume>398</volume>:<fpage>387</fpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(21)01453-7</pub-id><pub-id pub-id-type="pmid">34273293</pub-id><pub-id pub-id-type="pmcid">PMC8279961</pub-id></mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thunstr&#246;m</surname><given-names>L</given-names></name><name name-style="western"><surname>Ashworth</surname><given-names>M</given-names></name><name name-style="western"><surname>Finnoff</surname><given-names>D</given-names></name><name name-style="western"><surname>Newbold</surname><given-names>SC</given-names></name></person-group>. <article-title>Hesitancy toward a COVID-19 vaccine</article-title>. <source>Ecohealth.</source> (<year>2021</year>) <volume>18</volume>:<fpage>44</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1007/s10393-021-01524-0</pub-id><pub-id pub-id-type="pmid">34086129</pub-id><pub-id pub-id-type="pmcid">PMC8175934</pub-id></mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Babicki</surname><given-names>M</given-names></name><name name-style="western"><surname>Pokorna-Ka&#322;wak</surname><given-names>D</given-names></name><name name-style="western"><surname>Doniec</surname><given-names>Z</given-names></name><name name-style="western"><surname>Mastalerz-Migas</surname><given-names>A</given-names></name></person-group>. <article-title>Attitudes of parents with regard to vaccination of children against COVID-19 in Poland. a nationwide online survey</article-title>. <source>Vaccines.</source> (<year>2021</year>) <volume>9</volume>:<fpage>1192</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines9101192</pub-id><pub-id pub-id-type="pmid">34696300</pub-id><pub-id pub-id-type="pmcid">PMC8539339</pub-id></mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Humble</surname><given-names>RM</given-names></name><name name-style="western"><surname>Sell</surname><given-names>H</given-names></name><name name-style="western"><surname>Dub&#233;</surname><given-names>E</given-names></name><name name-style="western"><surname>MacDonald</surname><given-names>NE</given-names></name><name name-style="western"><surname>Robinson</surname><given-names>J</given-names></name><name name-style="western"><surname>Driedger</surname><given-names>SM</given-names></name><etal/></person-group>. <article-title>Canadian parents' perceptions of COVID-19 vaccination and intention to vaccinate their children: Results from a cross-sectional national survey</article-title>. <source>Vaccine.</source> (<year>2021</year>). <pub-id pub-id-type="doi">10.1016/j.vaccine.2021.10.002</pub-id><pub-id pub-id-type="pmid">34688500</pub-id><pub-id pub-id-type="pmcid">PMC8500474</pub-id></mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kezhong</surname><given-names>A</given-names></name><name name-style="western"><surname>Lu</surname><given-names>X</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Hu</surname><given-names>L</given-names></name><name name-style="western"><surname>Li</surname><given-names>B</given-names></name><name name-style="western"><surname>Lu</surname><given-names>Y</given-names></name></person-group>. <article-title>Association between adult vaccine hesitancy and parental acceptance of childhood COVID-19 vaccines: a web-based survey in a Northwestern Region in China</article-title>. <source>Vaccines</source>. (<year>2021</year>) <volume>9</volume>:<fpage>1088</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines9101088</pub-id><pub-id pub-id-type="pmid">34696196</pub-id><pub-id pub-id-type="pmcid">PMC8539638</pub-id></mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Polack</surname><given-names>FP</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine</article-title>. <source>N Engl J Med.</source> (<year>2020</year>) <volume>383</volume>:<fpage>2603</fpage>&#8211;<lpage>15</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2034577</pub-id><pub-id pub-id-type="pmid">33301246</pub-id><pub-id pub-id-type="pmcid">PMC7745181</pub-id></mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Baden</surname><given-names>LR</given-names></name><name name-style="western"><surname>El Sahly</surname><given-names>HM</given-names></name><name name-style="western"><surname>Essink</surname><given-names>B</given-names></name><name name-style="western"><surname>Kotloff</surname><given-names>K</given-names></name><name name-style="western"><surname>Frey</surname><given-names>S</given-names></name><name name-style="western"><surname>Novak</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine</article-title>. <source>N Engl J Med.</source> (<year>2021</year>) <volume>384</volume>:<fpage>403</fpage>&#8211;<lpage>16</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2035389</pub-id><pub-id pub-id-type="pmid">33378609</pub-id><pub-id pub-id-type="pmcid">PMC7787219</pub-id></mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walsh</surname><given-names>EE</given-names></name><name name-style="western"><surname>Frenck</surname><given-names>RW</given-names></name><name name-style="western"><surname>Falsey</surname><given-names>AR</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates</article-title>. <source>N Engl J Med.</source> (<year>2020</year>) <volume>383</volume>:<fpage>2439</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2027906</pub-id><pub-id pub-id-type="pmid">33053279</pub-id><pub-id pub-id-type="pmcid">PMC7583697</pub-id></mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>Z</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xu</surname><given-names>M</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial</article-title>. <source>Lancet Infect Dis.</source> (<year>2021</year>) <volume>21</volume>:<fpage>803</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30987-7</pub-id><pub-id pub-id-type="pmid">33548194</pub-id><pub-id pub-id-type="pmcid">PMC7906628</pub-id></mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial</article-title>. <source>Lancet Infect Dis.</source> (<year>2021</year>) <volume>21</volume>:<fpage>39</fpage>&#8211;<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(20)30831-8</pub-id><pub-id pub-id-type="pmid">33069281</pub-id><pub-id pub-id-type="pmcid">PMC7561304</pub-id></mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Al Kaabi</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Al Qahtani</surname><given-names>MM</given-names></name><name name-style="western"><surname>Abdulrazzaq</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial</article-title>. <source>JAMA.</source> (<year>2021</year>) <volume>326</volume>:<fpage>35</fpage>&#8211;<lpage>45</lpage>. <pub-id pub-id-type="doi">10.1001/jama.2021.8565</pub-id><pub-id pub-id-type="pmid">34037666</pub-id><pub-id pub-id-type="pmcid">PMC8156175</pub-id></mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramasamy</surname><given-names>MN</given-names></name><name name-style="western"><surname>Minassian</surname><given-names>AM</given-names></name><name name-style="western"><surname>Ewer</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Flaxman</surname><given-names>AL</given-names></name><name name-style="western"><surname>Folegatti</surname><given-names>PM</given-names></name><name name-style="western"><surname>Owens</surname><given-names>DR</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial</article-title>. <source>Lancet.</source> (<year>2021</year>) <volume>396</volume>:<fpage>1979</fpage>&#8211;<lpage>93</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(20)32466-1</pub-id><pub-id pub-id-type="pmid">33220855</pub-id><pub-id pub-id-type="pmcid">PMC7674972</pub-id></mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Logunov</surname><given-names>DY</given-names></name><name name-style="western"><surname>Dolzhikova</surname><given-names>IV</given-names></name><name name-style="western"><surname>Shcheblyakov</surname><given-names>DV</given-names></name><name name-style="western"><surname>Tukhvatulin</surname><given-names>AI</given-names></name><name name-style="western"><surname>Zubkova</surname><given-names>OV</given-names></name><name name-style="western"><surname>Dzharullaeva</surname><given-names>AS</given-names></name><etal/></person-group>. <article-title>Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia</article-title>. <source>Lancet.</source> (<year>2021</year>) <volume>397</volume>:<fpage>671</fpage>&#8211;<lpage>81</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(21)00234-8</pub-id><pub-id pub-id-type="pmid">33545094</pub-id><pub-id pub-id-type="pmcid">PMC7852454</pub-id></mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moher</surname><given-names>D</given-names></name><name name-style="western"><surname>Shamseer</surname><given-names>L</given-names></name><name name-style="western"><surname>Clarke</surname><given-names>M</given-names></name><name name-style="western"><surname>Ghersi</surname><given-names>D</given-names></name><name name-style="western"><surname>Liberati</surname><given-names>A</given-names></name><name name-style="western"><surname>Petticrew</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement</article-title>. <source>Syst Rev.</source> (<year>2015</year>) <volume>4</volume>:<fpage>1</fpage>. <pub-id pub-id-type="doi">10.1186/2046-4053-4-1</pub-id><pub-id pub-id-type="pmid">25554246</pub-id><pub-id pub-id-type="pmcid">PMC4320440</pub-id></mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation publication-type="book"><person-group person-group-type="author"><name name-style="western"><surname>Handbook</surname><given-names>C</given-names></name></person-group>. <source>Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. Updated March 2011</source>. <publisher-loc>Oxford</publisher-loc>: <publisher-name>The Cochrane Collaboration</publisher-name> (<year>2011</year>).</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Higgins J</surname><given-names>P</given-names></name><name name-style="western"><surname>Thompson S</surname><given-names>G</given-names></name><name name-style="western"><surname>Deeks J</surname><given-names>J</given-names></name><name name-style="western"><surname>Altman</surname><given-names>DG</given-names></name></person-group>. <article-title>Measuring inconsistency in meta-analyses</article-title>. <source>BMJ.</source> (<year>2003</year>) <volume>327</volume>:<fpage>557</fpage>&#8211;<lpage>60</lpage>. <pub-id pub-id-type="doi">10.1136/bmj.327.7414.557</pub-id><pub-id pub-id-type="pmid">12958120</pub-id><pub-id pub-id-type="pmcid">PMC192859</pub-id></mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nikolakopoulou</surname><given-names>A</given-names></name><name name-style="western"><surname>Mavridis</surname><given-names>D</given-names></name><name name-style="western"><surname>Salanti</surname><given-names>G</given-names></name></person-group>. <article-title>Demystifying fixed and random effects meta-analysis</article-title>. <source>Evid Based Ment Health.</source> (<year>2014</year>) <volume>17</volume>:<fpage>53</fpage>&#8211;<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1136/eb-2014-101795</pub-id><pub-id pub-id-type="pmid">24692250</pub-id></mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sterne</surname><given-names>JA</given-names></name><name name-style="western"><surname>Sutton</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Ioannidis</surname><given-names>JP</given-names></name><name name-style="western"><surname>Terrin</surname><given-names>N</given-names></name><name name-style="western"><surname>Jones</surname><given-names>DR</given-names></name><name name-style="western"><surname>Lau</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials</article-title>. <source>BMJ.</source> (<year>2011</year>) <volume>343</volume>:<fpage>d4002</fpage>. <pub-id pub-id-type="doi">10.1136/bmj.d4002</pub-id><pub-id pub-id-type="pmid">21784880</pub-id></mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ali</surname><given-names>K</given-names></name><name name-style="western"><surname>Berman</surname><given-names>G</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Deng</surname><given-names>W</given-names></name><name name-style="western"><surname>Faughnan</surname><given-names>V</given-names></name><name name-style="western"><surname>Coronado-Voges</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents</article-title>. <source>N Engl J Med.</source> (<year>2021</year>). <pub-id pub-id-type="doi">10.1056/NEJMoa2109522</pub-id><pub-id pub-id-type="pmid">34379915</pub-id><pub-id pub-id-type="pmcid">PMC8385554</pub-id></mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frenck</surname><given-names>RW</given-names></name><name name-style="western"><surname>Klein</surname><given-names>NP</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Safety, Immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents</article-title>. <source>N Engl J Med.</source> (<year>2021</year>) <volume>385</volume>:<fpage>239</fpage>&#8211;<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2107456</pub-id><pub-id pub-id-type="pmid">34043894</pub-id><pub-id pub-id-type="pmcid">PMC8174030</pub-id></mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Walter</surname><given-names>EB</given-names></name><name name-style="western"><surname>Talaat</surname><given-names>KR</given-names></name><name name-style="western"><surname>Sabharwal</surname><given-names>C</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name><name name-style="western"><surname>Paulsen</surname><given-names>GC</given-names></name><etal/></person-group>. <article-title>Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 years of age</article-title>. <source>N Engl J Med.</source> (<year>2021</year>). <pub-id pub-id-type="doi">10.1056/NEJMoa2116298</pub-id><pub-id pub-id-type="pmid">34752019</pub-id><pub-id pub-id-type="pmcid">PMC8609605</pub-id></mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Han</surname><given-names>B</given-names></name><name name-style="western"><surname>Song</surname><given-names>Y</given-names></name><name name-style="western"><surname>Li</surname><given-names>C</given-names></name><name name-style="western"><surname>Yang</surname><given-names>W</given-names></name><name name-style="western"><surname>Ma</surname><given-names>Q</given-names></name><name name-style="western"><surname>Jiang</surname><given-names>Z</given-names></name><etal/></person-group>. <article-title>Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial</article-title>. <source>Lancet Infect Dis.</source> (<year>2021</year>) <volume>21</volume>:<fpage>1645</fpage>&#8211;<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(21)00319-4</pub-id><pub-id pub-id-type="pmid">34197764</pub-id><pub-id pub-id-type="pmcid">PMC8238449</pub-id></mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xia</surname><given-names>S</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>H</given-names></name><name name-style="western"><surname>Yang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>GF</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial</article-title>. <source>Lancet Infect Dis.</source> (<year>2021</year>). <pub-id pub-id-type="doi">10.1016/S1473-3099(21)00462-X</pub-id><pub-id pub-id-type="pmid">34536349</pub-id><pub-id pub-id-type="pmcid">PMC8443232</pub-id></mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhu</surname><given-names>F</given-names></name><name name-style="western"><surname>Jin</surname><given-names>P</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>T</given-names></name><name name-style="western"><surname>Wang</surname><given-names>W</given-names></name><name name-style="western"><surname>Ye</surname><given-names>H</given-names></name><name name-style="western"><surname>Pan</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of a recombinant adenovirus type-5-vectored COVID-19 vaccine with a homologous prime-boost regimen in healthy participants aged 6 years and above: a randomised, double-blind, placebo-controlled, phase 2b trial</article-title>. <source>Clin Infect Dis.</source> (<year>2021</year>). <pub-id pub-id-type="doi">10.1093/cid/ciab845</pub-id><pub-id pub-id-type="pmid">34551104</pub-id><pub-id pub-id-type="pmcid">PMC8522421</pub-id></mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ella</surname><given-names>R</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>S</given-names></name><name name-style="western"><surname>Jogdand</surname><given-names>H</given-names></name><name name-style="western"><surname>Sarangi</surname><given-names>V</given-names></name><name name-style="western"><surname>Ganneru</surname><given-names>B</given-names></name><name name-style="western"><surname>Prasad</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial</article-title>. <source>Lancet Infect Dis.</source> (<year>2021</year>) <volume>21</volume>:<fpage>950</fpage>&#8211;<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1016/S1473-3099(21)00070-0</pub-id><pub-id pub-id-type="pmid">33705727</pub-id><pub-id pub-id-type="pmcid">PMC8221739</pub-id></mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Thomas</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Moreira</surname><given-names>ED</given-names></name><name name-style="western"><surname>Kitchin</surname><given-names>N</given-names></name><name name-style="western"><surname>Absalon</surname><given-names>J</given-names></name><name name-style="western"><surname>Gurtman</surname><given-names>A</given-names></name><name name-style="western"><surname>Lockhart</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine through 6 months</article-title>. <source>N Engl J Med.</source> (<year>2021</year>) <volume>385</volume>:<fpage>1761</fpage>&#8211;<lpage>73</lpage>. <pub-id pub-id-type="doi">10.1056/NEJMoa2110345</pub-id><pub-id pub-id-type="pmid">34525277</pub-id><pub-id pub-id-type="pmcid">PMC8461570</pub-id></mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lv</surname><given-names>M</given-names></name><name name-style="western"><surname>Luo</surname><given-names>X</given-names></name><name name-style="western"><surname>Shen</surname><given-names>Q</given-names></name><name name-style="western"><surname>Lei</surname><given-names>R</given-names></name><name name-style="western"><surname>Liu</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Safety, Immunogenicity, and efficacy of COVID-19 vaccines in children and adolescents: a systematic review</article-title>. <source>Vaccines.</source> (<year>2021</year>) <volume>9</volume>:<fpage>1102</fpage>. <pub-id pub-id-type="doi">10.3390/vaccines9101102</pub-id><pub-id pub-id-type="pmid">34696210</pub-id><pub-id pub-id-type="pmcid">PMC8539812</pub-id></mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Boehmer</surname><given-names>TK</given-names></name><name name-style="western"><surname>Kompaniyets</surname><given-names>L</given-names></name><name name-style="western"><surname>Lavery</surname><given-names>AM</given-names></name><name name-style="western"><surname>Hsu</surname><given-names>J</given-names></name><name name-style="western"><surname>Ko</surname><given-names>JY</given-names></name><name name-style="western"><surname>Yusuf</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Association between COVID-19 and myocarditis using hospital-based administrative data - United States, March 2020-January 2021</article-title>. <source>MMWR Morb Mortal Wkly Rep.</source> (<year>2021</year>) <volume>70</volume>:<fpage>1228</fpage>&#8211;<lpage>32</lpage>. <pub-id pub-id-type="doi">10.15585/mmwr.mm7035e5</pub-id><pub-id pub-id-type="pmid">34473684</pub-id><pub-id pub-id-type="pmcid">PMC8422872</pub-id></mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>J</given-names></name><name name-style="western"><surname>Wang</surname><given-names>J</given-names></name><name name-style="western"><surname>Xu</surname><given-names>J</given-names></name><name name-style="western"><surname>Xia</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Comprehensive investigations revealed consistent pathophysiological alterations after vaccination with COVID-19 vaccines</article-title>. <source>Cell Discov.</source> (<year>2021</year>) <volume>7</volume>:<fpage>99</fpage>. <pub-id pub-id-type="doi">10.1038/s41421-021-00329-3</pub-id><pub-id pub-id-type="pmid">34697287</pub-id><pub-id pub-id-type="pmcid">PMC8546144</pub-id></mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kaushik</surname><given-names>A</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>S</given-names></name><name name-style="western"><surname>Sood</surname><given-names>M</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>S</given-names></name><name name-style="western"><surname>Verma</surname><given-names>S. A</given-names></name></person-group>. <article-title>Systematic review of multisystem inflammatory syndrome in children associated with SARS-CoV-2 infection</article-title>. <source>Pediatr Infect Dis J.</source> (<year>2020</year>) <volume>39</volume>:<fpage>e340</fpage>&#8211;<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/INF.0000000000002888</pub-id><pub-id pub-id-type="pmid">32925547</pub-id></mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation publication-type="webpage"><person-group person-group-type="author"><collab>Pfizer</collab></person-group>. <source>Pfizer And BioNTech Receive Positive CHMP Opinion For COMIRNATY&#174; In Children 5 To&lt;12 Years Of Age In The European Union</source>. (<year>2021</year>). Available online at: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion" ext-link-type="uri">https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-positive-chmp-opinion</ext-link> (accessed November 25, 2021).</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Prabhu</surname><given-names>M</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>EA</given-names></name><name name-style="western"><surname>Sukhu</surname><given-names>AC</given-names></name><name name-style="western"><surname>Yee</surname><given-names>J</given-names></name><name name-style="western"><surname>Singh</surname><given-names>S</given-names></name><name name-style="western"><surname>Eng</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Antibody response to coronavirus disease 2019 (COVID-19) messenger RNA vaccination in pregnant women and transplacental passage into cord blood</article-title>. <source>Obstet Gynecol.</source> (<year>2021</year>) <volume>138</volume>:<fpage>278</fpage>&#8211;<lpage>80</lpage>. <pub-id pub-id-type="doi">10.1097/AOG.0000000000004438</pub-id><pub-id pub-id-type="pmid">33910219</pub-id><pub-id pub-id-type="pmcid">PMC8288193</pub-id></mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Beharier</surname><given-names>O</given-names></name><name name-style="western"><surname>Plitman Mayo</surname><given-names>R</given-names></name><name name-style="western"><surname>Raz</surname><given-names>T</given-names></name><name name-style="western"><surname>Nahum Sacks</surname><given-names>K</given-names></name><name name-style="western"><surname>Schreiber</surname><given-names>L</given-names></name><name name-style="western"><surname>Suissa-Cohen</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine</article-title>. <source>J Clin Invest.</source> (<year>2021</year>) <volume>131</volume>:<fpage>e150319</fpage>. <pub-id pub-id-type="doi">10.1172/JCI150319</pub-id><pub-id pub-id-type="pmid">34596052</pub-id><pub-id pub-id-type="pmcid">PMC8483743</pub-id></mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gray</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Bordt</surname><given-names>EA</given-names></name><name name-style="western"><surname>Atyeo</surname><given-names>C</given-names></name><name name-style="western"><surname>Deriso</surname><given-names>E</given-names></name><name name-style="western"><surname>Akinwunmi</surname><given-names>B</given-names></name><name name-style="western"><surname>Young</surname><given-names>N</given-names></name><etal/></person-group>. <article-title>Coronavirus disease 2019 vaccine response in pregnant and lactating women: a cohort study</article-title>. <source>Am J Obstet Gynecol.</source> (<year>2021</year>) <volume>225</volume>:<fpage>303</fpage>. <pub-id pub-id-type="doi">10.1016/j.ajog.2021.03.023</pub-id><pub-id pub-id-type="pmid">33775692</pub-id><pub-id pub-id-type="pmcid">PMC7997025</pub-id></mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tran Kiem</surname><given-names>C</given-names></name><name name-style="western"><surname>Massonnaud</surname><given-names>CR</given-names></name><name name-style="western"><surname>Levy-Bruhl</surname><given-names>D</given-names></name><name name-style="western"><surname>Poletto</surname><given-names>C</given-names></name><name name-style="western"><surname>Colizza</surname><given-names>V</given-names></name><name name-style="western"><surname>Bosetti</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>A modelling study investigating short and medium-term challenges for COVID-19 vaccination: From prioritisation to the relaxation of measures</article-title>. <source>EClinicalMedicine.</source> (<year>2021</year>) <volume>38</volume>:<fpage>101001</fpage>. <pub-id pub-id-type="doi">10.1016/j.eclinm.2021.101001</pub-id><pub-id pub-id-type="pmid">34278284</pub-id><pub-id pub-id-type="pmcid">PMC8278244</pub-id></mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Russell F</surname><given-names>M</given-names></name><name name-style="western"><surname>Greenwood</surname><given-names>B</given-names></name></person-group>. <article-title>Who should be prioritised for COVID-19 vaccination?</article-title><source>Hum Vaccin Immunother.</source> (<year>2021</year>) <volume>17</volume>:<fpage>1317</fpage>&#8211;<lpage>21</lpage>. <pub-id pub-id-type="doi">10.1080/21645515.2020.1827882</pub-id><pub-id pub-id-type="pmid">33141000</pub-id><pub-id pub-id-type="pmcid">PMC8078651</pub-id></mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cerda</surname><given-names>AA</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>LY</given-names></name></person-group>. <article-title>Hesitation and refusal factors in individuals' decision-making processes regarding a coronavirus disease 2019 vaccination</article-title>. <source>Front Public Health.</source> (<year>2021</year>) <volume>9</volume>:<fpage>626852</fpage>. <pub-id pub-id-type="doi">10.3389/fpubh.2021.626852</pub-id><pub-id pub-id-type="pmid">33968880</pub-id><pub-id pub-id-type="pmcid">PMC8096991</pub-id></mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cerda</surname><given-names>AA</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>LY</given-names></name></person-group>. <article-title>Factors explaining the fear of being infected with COVID-19</article-title>. <source>Health Expect.</source> (<year>2022</year>) <volume>25</volume>:<fpage>506</fpage>&#8211;<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1111/hex.13274</pub-id><pub-id pub-id-type="pmid">33974721</pub-id><pub-id pub-id-type="pmcid">PMC8239863</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>